<!DOCTYPE html>
<html>
<head>

<script id="f5_cspm">
(function(){var f5_cspm={f5_p:'CEBDNHALAOEBOOPGEBOKDBDHMJDJNKCEGOABJPEIPGDBFFLPEDMKPDKHODAAGPMPCKCEMGDMCBGDLCJCAELHOOLIAPIHJJEEGJOACLBNECIHCIOOJAGBKGKDEFLEHEGB',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,32,(latency>>8));str=f5_cspm.set_byte(str,33,(latency&0xff));str=f5_cspm.set_byte(str,27,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='aaaaaaaaaaaaaaa='+encodeURIComponent(cookie_val)+';path=/';}
return;}}
catch(err){return;}
setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'){if(pair[1]=='1234'){var d=new Date();d.setTime(d.getTime()-1);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;';setTimeout(f5_cspm.wait_perf_data,100);}}}}}
f5_cspm.go();}());
</script>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta charset="utf-8">
<title>DailyMed - PRISTIQ EXTENDED-RELEASE- desvenlafaxine
succinate tablet, extended release</title>
<!--[if lt IE 9]>
        <script src="/dailymed/scripts/html5shiv.min.js"></script>
    <![endif]-->

<script src="/dailymed/scripts/modernizr-2.0.6.min.js">
</script>
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/skeleton.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/jquery.jqzoom.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/style.min.css?v=2">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/header-search.min.css">
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive.min.css">
<link rel="stylesheet" type="text/css" media="print" href=
"/dailymed/css/print.min.css"><!--[if !IE]><!-->
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive-tables.min.css"><!--<![endif]-->
<link rel="icon" href="/dailymed/images/favicons/favicon.ico" type=
"image/x-icon">
<link rel="shortcut icon" href=
"/dailymed/images/favicons/favicon.ico" type="image/x-icon">
<link rel="apple-touch-icon" sizes="57x57" href=
"/dailymed/images/favicons/apple-touch-icon-57x57.png">
<link rel="apple-touch-icon" sizes="114x114" href=
"/dailymed/images/favicons/apple-touch-icon-114x114.png">
<link rel="apple-touch-icon" sizes="72x72" href=
"/dailymed/images/favicons/apple-touch-icon-72x72.png">
<link rel="apple-touch-icon" sizes="144x144" href=
"/dailymed/images/favicons/apple-touch-icon-144x144.png">
<link rel="apple-touch-icon" sizes="60x60" href=
"/dailymed/images/favicons/apple-touch-icon-60x60.png">
<link rel="apple-touch-icon" sizes="120x120" href=
"/dailymed/images/favicons/apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" sizes="76x76" href=
"/dailymed/images/favicons/apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" sizes="152x152" href=
"/dailymed/images/favicons/apple-touch-icon-152x152.png">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-196x196.png" sizes="196x196">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-160x160.png" sizes="160x160">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-96x96.png" sizes="96x96">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-16x16.png" sizes="16x16">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-32x32.png" sizes="32x32">
<meta name="msapplication-config" content=
"/dailymed/images/favicons/browserconfig.xml">
<meta name="msapplication-TileColor" content="#da532c">
<meta name="msapplication-TileImage" content=
"/dailymed/images/favicons/mstile-144x144.png">
<meta name="description" content="">
<meta name="keywords" content="">
<meta name="robots" content="noimageindex, noodp, noydir">
<meta name="viewport" id="viewport" content=
"width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0"><!-- Magnific Popup core CSS file -->
<link rel="stylesheet" href="/dailymed/css/magnific-popup.min.css">
<meta name="format-detection" content="telephone=no">
</head>
<body class="inner drug-info">
<div class="container_1000 bg_shadow">
<div style="width: 0; height: 0;"><a href="#" id=
"top-of-page"></a></div>
<header>
<div class="topHeader">
<ul id="skip">
<li><a href="#skip-main-content">Skip to Main Content</a></li>
</ul>
<nav class="topHeaderNav">
<div class="topNIHLogo mobileview"><a href="http://www.nih.gov"
class="top-logo" title="National Institutes of Health" target=
"_blank"><img src="/dailymed/images/nih-toplogo.png" alt=
"NIH Logo"></a> <a href="//www.nlm.nih.gov" title=
"U.S. National Library of Medicine" target="_blank">U.S. National
Library of Medicine</a></div>
<div class="container">
<div class="sixteen columns">
<div class="topNIHLogo"><a href="http://www.nih.gov" title=
"National Institutes of Health" target="_blank"><img src=
"/dailymed/images/nih-toplogo.png" alt="NIH Logo"></a> <a href=
"//www.nlm.nih.gov" title="U.S. National Library of Medicine"
target="_blank">U.S. National Library of Medicine</a></div>
<ul>
<li class="safety"><a title="Report Adverse Events" href=
"//www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report
Adverse Events</a> <span>|</span><a title=
"FDA Safety Reporting and Recalls" href=
"http://www.fda.gov/Safety/Recalls" target=
"_blank">Recalls</a></li>
</ul>
</div>
</div>
</nav>
<div class="divider"></div>
</div>
<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png"
alt="DailyMed"></div>
<div class="bottomHeader">
<div class="header-image">
<div class="mobile-menu-btn closed hasjs" tabindex="0"></div>
<div class="mobile-menu">
<div class="mobile-menu-container">
<div class="pro-menu active">
<div class="first half">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/about-dailymed.cfm">About Dailymed</a></li>
<li><a href="/dailymed/contact-us.cfm">Contact Us</a></li>
<li>Safety Reporting &amp; Recalls
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/">Report
Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey
Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
</ul>
</div>
<div class="last half">
<ul>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-all-mapping-files.cfm">Articles &amp;
Presentations</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</div>
</div>
<a href="/dailymed/index.cfm" class="logo" title=
"DailyMed">DailyMed</a>
<div class="header-search-container">
<div id="header-search">
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all" value="all"> <label for=
"labeltype-all">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human" value="human"> <label for=
"labeltype-human">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal" value="animal"> <label for=
"labeltype-animal">Animal Drugs</label></li>
<li class="more-ways" id="header-search-more-ways"><a href="#" id=
"more-ways-button" class="more-ways-label">More ways to search</a>
<ul id="more-ways-dropdown" class="dropdown" style="display:none;">
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Label Archives</a></li>
<li><a class="external-link" href="http://pillbox.nlm.nih.gov"
target="_blank">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
</div>
</div>
<div class="mobile-search-btn" tabindex="0"></div>
<div class="header-bg"></div>
<div class="divider"></div>
</div>
<div class="bottomHeaderContent">
<div class="search mobile-search">
<div class="divider_10 nomargin mobileview"></div>
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all-2" value="all"> <label for=
"labeltype-all-2">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human-2" value="human"> <label for=
"labeltype-human-2">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal-2" value="animal"> <label for=
"labeltype-animal-2">Animal Drugs</label></li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchToolsQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
<div class="divider"></div>
<nav class="bottomHeaderNav"><noscript>
<div class="tabletnav no-js">
<div class="col">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</noscript>
<ul class="webview hasjs">
<li><a href="/dailymed/index.cfm" title="Home">Home</a></li>
<li><a href="#" title="News">News</a>
<ul class="sub-menu">
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm" title=
"FDA Guidances &amp; Info">FDA Guidances &amp; Info</a></li>
<li><a href="#" title=
"Structured Product Labeling (SPL) resources for industry professionals.">
NLM SPL Resources</a>
<ul class="sub-menu">
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><a href="#" title="Application Development Support">Application
Development Support</a>
<ul class="sub-menu">
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
<ul class="tabletview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li class="viewmore"><a href="#" title="View More">View More</a>
<ul>
<li><span>News</span>
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><span>Safety Reporting and Recalls</span>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="//www.fda.gov/Safety/Recalls" target="_blank">FDA
Saftey Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li><span>NLM SPL Resources</span>
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><span>Application Development Support</span>
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
</li>
<li class="mobileview viewmore" tabindex="0"><a title="View More"
href="#">More ways to search</a>
<ul>
<li tabindex="0"><a title="Browse Drug Classes" href=
"/dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>
<li tabindex="0"><a title="Label Archives" href=
"/dailymed/archives/index.cfm">Label Archives</a></li>
<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool"
href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
<ul class="mobileview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li tabindex="0" class="viewmore"><a href="#" title=
"View More">View More</a>
<ul>
<li tabindex="0"><a href="/dailymed/browse-drug-classes.cfm" title=
"Browse Drug Classes">Browse Drug Classes</a></li>
<li tabindex="0"><a href="/dailymed/archives/index.cfm" title=
"Label Archives">Label Archives</a></li>
<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title=
"Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</nav>
<div class="divider_10 nomargin"></div>
</div>
</div>
<div class="divider"></div>
</div>
</header>
<div id="skip-main-content"></div>
<div class="container">
<div class="main-content">
<div class="header long">
<div class="header-top">
<h1>Label: <span class="long-title">PRISTIQ EXTENDED-RELEASE-
desvenlafaxine succinate tablet, extended release<br></span></h1>
</div>
<ul class="tools">
<li class="rss"><a href="#modal-label-rss" class="modal-open">Label
RSS</a></li>
<li class="share">Share <noscript>: JavaScript needed for Sharing
tools</noscript> <!-- AddThis Button BEGIN -->
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0APRISTIQ%20EXTENDED%2DRELEASE%2D%20Desvenlafaxine%20Succinate%20Tablet%2C%20Extended%20Release%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D0f43610c%2Df290%2D46ea%2Dd186%2D4f998ed99fce%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="display: block;"><span style=
"left: -9999px; position: absolute;">Bookmark &amp;
Share</span><img style="width:17px" src=
"/dailymed/images/addthis-image.jpg"></a></div>
<script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <!-- AddThis Button END --></li>
</ul>
</div>
<div class="four columns sidebar" id="leftmenu">
<section>
<article>
<div class="w-photos">
<div class="mod drug-photos">
<h2><a>View Package Photos</a></h2>
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=pristiq-08.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="0"><img id="zoom_1" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=pristiq-08.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
src=
"image.cfm?type=img&amp;name=pristiq-08.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=pristiq-09.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="1"><img id="zoom_2" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=pristiq-09.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
src=
"image.cfm?type=img&amp;name=pristiq-09.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
<h4 class="more closed">VIEW MORE</h4>
<div class="show-more">
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=pristiq-10.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="2"><img id="zoom_3" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=pristiq-10.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
src=
"image.cfm?type=img&amp;name=pristiq-10.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=pristiq-11.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="3"><img id="zoom_4" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=pristiq-11.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
src=
"image.cfm?type=img&amp;name=pristiq-11.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
data-photo-type="package"> </a></li>
</ul>
</li>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=pristiq-12.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="4"><img id="zoom_5" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=pristiq-12.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
src=
"image.cfm?type=img&amp;name=pristiq-12.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=pristiq-13.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="5"><img id="zoom_6" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=pristiq-13.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
src=
"image.cfm?type=img&amp;name=pristiq-13.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
data-photo-type="package"> </a></li>
</ul>
</li>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=pristiq-14.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="6"><img id="zoom_7" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=pristiq-14.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
src=
"image.cfm?type=img&amp;name=pristiq-14.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=pristiq-15.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="7"><img id="zoom_8" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=pristiq-15.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
src=
"image.cfm?type=img&amp;name=pristiq-15.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
data-photo-type="package"> </a></li>
</ul>
</li>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=pristiq-16.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="8"><img id="zoom_9" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=pristiq-16.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
src=
"image.cfm?type=img&amp;name=pristiq-16.jpg&amp;setid=0f43610c-f290-46ea-d186-4f998ed99fce"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
</div>
</div>
<div class="mod drug-photos">
<h2><a>VIEW DRUG PHOTOS</a></h2>
<div class="no-pill-photo-warning-drug-info">DailyMed is no longer
displaying pill images from RxImage. For more information, <a href=
"#no-pill-photo-warning-modal" class="modal-open">click
here</a>.</div>
</div>
</div>
<div class="mod-wrap">
<div class="mod blue-list page-jump">
<h2><a href="#drug-information">Drug Label Info</a></h2>
</div>
<div class="mod blue-list orange">
<h2><a href="#">Safety</a></h2>
<ul>
<li><a class="tip" rel="tooltip" title=
"A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects."
href="#boxedwarning">Boxed Warnings</a></li>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls/" target=
"_blank">FDA Safety Recalls</a></li>
<li><a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22DESVENLAFAXINE%22+%29"
target="_blank">Presence in Breast Milk</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">Related Resources</a></h2>
<ul>
<li><a href=
"//vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=DESVENLAFAXINE"
target="_blank">Medline Plus</a></li>
<li><a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=DESVENLAFAXINE"
target="blank">Clinical Trials</a></li>
<li><a href="#" id="pubmed-menu">PubMed</a>
<ul>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DESVENLAFAXINE[All%20Fields]"
title="Link opens new window for All Citations" target="pubmed">All
Citations</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DESVENLAFAXINE/AE"
title="Link opens new window for Adverse Effects" target=
"pubmed">Adverse Effects</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DESVENLAFAXINE/TU"
title="Link opens new window for Therapeutic Use" target=
"pubmed">Therapeutic Use</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DESVENLAFAXINE/PD"
title="Link opens new window for Pharmacology" target=
"pubmed">Pharmacology</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DESVENLAFAXINE[All%20Fields]%20AND%20Clinical%20Trial[ptyp]"
title="Link opens new window for Clinical Trials" target=
"pubmed">Clinical Trials</a></li>
</ul>
</li>
<li><a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=DESVENLAFAXINE+SUCCINATE&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">More Info For This Drug</a></h2>
<ul>
<li><a href="#modal-label-archives" class="modal-open">View Label
Archives</a></li>
<li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>
<li><a href="#modal-label-rss" class="modal-open">Get Label RSS
Feed</a></li>
</ul>
</div>
</div>
</article>
</section>
</div>
<div class="content-wide">
<article>
<ul class="drug-information">
<li><strong><a class="tip" rel="tooltip" title=
"&lt;b&gt;NDC (National Drug Code)&lt;/b&gt; - Each drug product is assigned this unique number which can be found on the drug's outer packaging."
href="#">NDC Code(s):</a></strong> <span id=
"item-code-s">0008-1210-30, 0008-1211-01, 0008-1211-14,
0008-1211-30, <a class="view-more show-js" href="#">view
more</a></span>
<div class="more-codes"><span id="item-code-s"><span>0008-1211-50,
0008-1211-70, 0008-1222-01, 0008-1222-14, 0008-1222-30,
0008-1222-50</span></span></div>
</li>
<li><strong>Packager:</strong> Wyeth Pharmaceuticals Inc., a
subsidiary of Pfizer Inc.</li>
</ul>
<ul class="drug-information">
<li><strong>Category:</strong> <span id="category" class=
"orangetext">HUMAN PRESCRIPTION DRUG LABEL</span></li>
<li><strong>DEA Schedule:</strong> <span id=
"dea-schedule">None</span></li>
<li><strong>Marketing Status:</strong> <span id=
"marketing-status">New Drug Application</span></li>
</ul>
<div id="drug-information" class="toggle">
<h2><a id="druglabel"></a>Drug Label Information</h2>
<p class="date">Updated March 30, 2015</p>
<p class="orangetext">If you are a consumer or patient please visit
<a class="audience-context-switch consumer" href=
"/dailymed/drugInfo.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;audience=consumer">
this version.</a></p>
<ul class="tools">
<li class="download">Download DRUG LABEL INFO: <a download=""
class="pdf" href=
"/dailymed/getFile.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;type=pdf&amp;name=0f43610c-f290-46ea-d186-4f998ed99fce"
target="_blank">PDF</a> <a download="" class="xml" href=
"/dailymed/getFile.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;type=zip&amp;name=PRISTIQ%20EXTENDED-RELEASE"
target="_blank">XML</a></li>
<li class="medguide">Medication Guide: <a href=
"/dailymed/medguide.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce"
target="_blank">HTML</a></li>
<li class="print"><a href=
"/dailymed/fda/fdaDrugXsl.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;type=display"
target="_blank">Print Drug Label Info</a></li>
</ul>
<div class="drug-label-sections">
<div class="control-nav show-js"><a class="open-all" href="#">View
All Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
<ul>
<li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip"
rel="tooltip" href="#" title=
"A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What
is this?)</a>
<div class="Warning toggle-content open"><a name="BOX" id=
"BOX"></a> <a name="section-1" id="section-1"></a>
<h1><span class="Emphasis">WARNING: SUICIDAL THOUGHTS AND
BEHAVIORS</span></h1>
<p class="First"><span class="Bold">Antidepressants increased the
risk of suicidal thoughts and behavior in children, adolescents,
and young adults in short-term studies. These studies did not show
an increase in the risk of suicidal thoughts and behavior with
antidepressant use in patients over age 24; there was a reduction
in risk with antidepressant use in patients aged 65 and older
[<span class="Italics">see <a href="#S5.1">Warnings and Precautions
(5.1)</a></span>].</span></p>
<p><span class="Bold">In patients of all ages who are started on
antidepressant therapy, monitor closely for worsening, and for
emergence of suicidal thoughts and behaviors. Advise families and
caregivers of the need for close observation and communication with
the prescriber [<span class="Italics">see <a href="#S5.1">Warnings
and Precautions (5.1)</a></span>].</span></p>
<p><span class="Bold">PRISTIQ is not approved for use in pediatric
patients [<span class="Italics">see <a href="#S8.4">Use in Specific
Populations (8.4)</a></span>].</span></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a>
<div id="Highlights" class=" Highlights toggle-content closed">
<div class="HighlightsDisclaimer">These highlights do not include
all the information needed to use PRISTIQ safely and effectively.
See full prescribing information for PRISTIQ.<br>
<br>
PRISTIQ <span class="Sup">®</span> (desvenlafaxine)
Extended-Release Tablets, for oral use<br>
Initial U.S. Approval: 2008</div>
<div class="Warning">
<div>
<h1 class="Warning">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing
information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">Increased risk of suicidal thinking and
behavior in children, adolescents and young adults taking
antidepressants (<a href="#S5.1">5.1</a>).</span></li>
<li><span class="Bold">Monitor for worsening and emergence of
suicidal thoughts and behaviors (<a href=
"#S5.1">5.1</a>).</span></li>
<li><span class="Bold">PRISTIQ is not approved for use in pediatric
patients (<a href="#S8.4">8.4</a>).</span></li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<table class="Noautorules" width="100%">
<colgroup>
<col align="left" valign="top" width="90%">
<col align="right" valign="top" width="10%"></colgroup>
<tbody class="Headless">
<tr>
<td align="left">Dosage and Administration, General Instruction for
Use (<a href="#S2.1">2.1</a>)</td>
<td align="right">04/2014</td>
</tr>
<tr>
<td align="left">Dosage and Administration, Special populations
(<a href="#S2.2">2.2</a>)</td>
<td align="right">07/2014</td>
</tr>
<tr>
<td align="left">Dosage and Administration, Discontinuing PRISTIQ
(<a href="#S2.4">2.4</a>)</td>
<td align="right">04/2014</td>
</tr>
<tr>
<td align="left">Warnings and Precautions, Angle Closure
Glaucoma(<a href="#S5.5">5.5</a>)</td>
<td align="right">05/2014</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">PRISTIQ, is a serotonin and norepinephrine
reuptake inhibitor (SNRI) indicated for the treatment of major
depressive disorder (MDD) (<a href="#S1">1</a>).</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul>
<li>Recommended dose: 50 mg once daily with or without food
(<a href="#S2.1">2.1</a>).</li>
<li>There was no evidence that doses greater than 50 mg per day
confer any additional benefit (<a href="#S2.1">2.1</a>).</li>
<li>The 25 mg per day dose is intended for a gradual reduction in
dose when discontinuing treatment or dosing in severe renal and
end-stage renal disease patients (<a href="#S2.1">2.1</a>).</li>
<li>Discontinuation: Reduce dose gradually whenever possible
(<a href="#S2.1">2.1</a>).</li>
<li>Take tablets whole; do not divide, crush, chew, or dissolve
(<a href="#S2.1">2.1</a>).</li>
<li>Moderate renal impairment: Maximum dose 50 mg per day (<a href=
"#S2.2">2.2</a>).</li>
<li>Severe renal impairment and end-stage renal disease: Maximum
dose 25 mg per day or 50 mg every other day (<a href=
"#S2.2">2.2</a>).</li>
<li>Moderate to severe hepatic impairment: Maximum dose 100 mg per
day (<a href="#S2.2">2.2</a>).</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<ul>
<li>PRISTIQ extended-release tablets: 25 mg, 50 mg and 100 mg
(<a href="#S3">3</a>).</li>
<li>Each tablet contains 38 mg, 76 mg or 152 mg of desvenlafaxine
succinate equivalent to 25 mg, 50 mg or 100 mg of desvenlafaxine,
respectively (<a href="#S3">3</a>).</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<ul>
<li>Hypersensitivity to desvenlafaxine succinate, venlafaxine
hydrochloride or any excipients in the PRISTIQ formulation
(4.1).</li>
<li><span class="Italics">Serotonin syndrome and MAOIs</span>: Do
not use MAOIs intended to treat psychiatric disorders with PRISTIQ
or within 7 days of stopping treatment with PRISTIQ. Do not use
PRISTIQ within 14 days of stopping an MAOI intended to treat
psychiatric disorders. In addition, do not start PRISTIQ in a
patient who is being treated with linezolid or intravenous
methylene blue (4.2).</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<ul>
<li><span class="Italics">Clinical Worsening/Suicide Risk:</span>
Monitor for clinical worsening and suicide risk (<a href=
"#S5.1">5.1</a>).</li>
<li><span class="Italics">Serotonin Syndrome:</span> Serotonin
syndrome has been reported with SSRIs and SNRIs, including with
PRISTIQ, both when taken alone, but especially when co-administered
with other serotonergic agents (including triptans, tricyclic
antidepressants, fentanyl, lithium, tramadol, tryptophan,
buspirone, and St. John's Wort). If such symptoms occur,
discontinue PRISTIQ and initiate supportive treatment. If
concomitant use of PRISTIQ with other serotonergic drugs is
clinically warranted, patients should be made aware of a potential
increased risk for serotonin syndrome, particularly during
treatment initiation and dose increases (<a href=
"#S5.2">5.2</a>).</li>
<li><span class="Italics">Elevated Blood Pressure:</span> Control
hypertension before initiating treatment. Monitor blood pressure
regularly during treatment (<a href="#S5.3">5.3</a>).</li>
<li><span class="Italics">Abnormal Bleeding:</span> PRISTIQ may
increase risk of bleeding events. Caution patients about risk of
bleeding associated with concomitant use of PRISTIQ and NSAIDs,
aspirin, or other drugs that affect coagulation (<a href=
"#S5.4">5.4</a>).</li>
<li><span class="Italics">Angle Closure Glaucoma:</span> Angle
closure glaucoma has occurred in patients with untreated
anatomically narrow angles treated with antidepressants. (<a href=
"#S5.5">5.5</a>)</li>
<li><span class="Italics">Activation of Mania/Hypomania:</span> Use
cautiously in patients with Bipolar Disorder. Caution patients
about risk of activation of mania/hypomania (<a href=
"#S5.6">5.6</a>).</li>
<li><span class="Italics">Discontinuation Syndrome:</span> Taper
dose when possible and monitor for discontinuation symptoms
(<a href="#S5.7">5.7</a>).</li>
<li><span class="Italics">Seizure:</span> Can occur. Use cautiously
in patients with seizure disorder (<a href="#S5.8">5.8</a>).</li>
<li><span class="Italics">Hyponatremia:</span> Can occur in
association with SIADH (<a href="#S5.9">5.9</a>).</li>
<li><span class="Italics">Interstitial Lung Disease and
Eosinophilic Pneumonia:</span> Can occur (<a href=
"#S5.10">5.10</a>).</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥5%
and twice the rate of placebo in the 50 or 100 mg dose groups)
were: nausea, dizziness, insomnia, hyperhidrosis, constipation,
somnolence, decreased appetite, anxiety, and specific male sexual
function disorders (<a href="#S6.1">6.1</a>).</p>
<br>
<p class="Highlighta"><span class="Bold">To report SUSPECTED
ADVERSE REACTIONS, contact Wyeth Pharmaceuticals Inc., a subsidiary
of Pfizer Inc., at 1-800-438-1985 or FDA at 1-800-FDA-1088
or</span> <span class=
"Italics Underline">www.fda.gov/medwatch</span></p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC
POPULATIONS</span></h1>
<div>
<ul>
<li>Pregnancy: Based on animal data, may cause fetal harm (<a href=
"#S8.1">8.1</a>).</li>
<li>Nursing Mothers: Discontinue drug or nursing taking into
consideration importance of drug to mother (<a href=
"#S8.3">8.3</a>).</li>
<li>Geriatric Use: There is an increased incidence of orthostatic
hypotension in desvenlafaxine treated patients ≥ 65 years (<a href=
"#S6.1">6.1</a> and <a href="#S8.5">8.5</a>).</li>
</ul>
</div>
</div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING
INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 3/2015</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a>
<div id="Index" class=" Index toggle-content closed">
<h1><a href="#section-1" class="toc"><span class=
"Emphasis">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND
USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND
ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 GENERAL INSTRUCTION FOR
USE</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Special
Populations</a></h2>
<h2><a href="#section-2.3" class="toc">2.3
Maintenance/Continuation/Extended Treatment</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Discontinuing
PRISTIQ</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Switching Patients From
Other Antidepressants to PRISTIQ</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Switching Patients To or
From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat
Psychiatric Disorders</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND
STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND
PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Suicidal Thoughts and
Behaviors in Children, Adolescents and Young Adults</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Serotonin
Syndrome</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Elevated Blood
Pressure</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Abnormal
Bleeding</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Angle Closure
Glaucoma</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Activation of
Mania/Hypomania</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Discontinuation
Syndrome</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Seizure</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Hyponatremia</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Interstitial Lung
Disease and Eosinophilic Pneumonia</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies
Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing
Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Monoamine Oxidase
Inhibitors (MAOI)</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Serotonergic
Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Drugs that Interfere
with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin)</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Potential for Other
Drugs to Affect Desvenlafaxine</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Potential for
Desvenlafaxine to Affect Other Drugs</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Other Drugs Containing
Desvenlafaxine or Venlafaxine</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Ethanol</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Drug-Laboratory Test
Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC
POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Other Patient
Factors</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND
DEPENDENCE</a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled
Substance</a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Human Experience with
Overdosage</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Management of
Overdosage</a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL
PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of
Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2
Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3
Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL
TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis,
Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND
HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING
INFORMATION</a></h1>
<dl class="Footnote">
<dt><a name="footnote-content" href="#footnote-reference-content"
id="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing
information are not listed.</dd>
</dl>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">1 INDICATIONS AND USAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34067-9"><a name="S1" id="S1"></a> <a name="section-1" id=
"section-1"></a>
<p class="First">PRISTIQ, a serotonin and norepinephrine reuptake
inhibitor (SNRI), is indicated for the treatment of major
depressive disorder (MDD) <span class="Italics">[see <a href=
"#S14">Clinical Studies (14)</a> and <a href="#S2.1">Dosage and
Administration (2.1)</a>]</span>. The efficacy of PRISTIQ has been
established in four short-term (8-week, placebo-controlled studies)
and two maintenance studies in adult outpatients who met DSM-IV
criteria for major depressive disorder.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">2 DOSAGE AND ADMINISTRATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34068-7"><a name="S2" id="S2"></a> <a name="section-2" id=
"section-2"></a>
<div class="Section" data-sectioncode="42229-5"><a name="S2.1" id=
"S2.1"></a> <a name="section-2.1" id="section-2.1"></a>
<h2>2.1 GENERAL INSTRUCTION FOR USE</h2>
<p class="First" style="border-left:1px solid;"><span class=
"XmChange">The recommended dose for PRISTIQ is 50 mg once daily,
with or without food. The 50 mg dose is both a starting dose and
the therapeutic dose. PRISTIQ should be taken at approximately the
same time each day. Tablets must be swallowed whole with fluid and
not divided, crushed, chewed, or dissolved.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In
clinical studies, doses of 10 mg to 400 mg per day were studied. In
clinical studies, doses of 50 mg to 400 mg per day were shown to be
effective, although no additional benefit was demonstrated at doses
greater than 50 mg per day and adverse reactions and
discontinuations were more frequent at higher doses.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The 25 mg
per day dose is intended for a gradual reduction in dose when
discontinuing treatment. When discontinuing therapy, gradual dose
reduction is recommended whenever possible to minimize
discontinuation symptoms <span class="Italics">[see <a href=
"#S2.4">Dosage and Administration (2.4)</a> and <a href=
"#S5.9">Warnings and Precautions (5.9)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S2.2" id=
"S2.2"></a> <a name="section-2.2" id="section-2.2"></a>
<h2>2.2 Special Populations</h2>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-2.2.1" id="section-2.2.1"></a>
<p class="First" style="border-left:1px solid;"><span class=
"XmChange"><span class="Underline">Patients with renal
impairment</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">The
maximum recommended dose in patients with moderate renal impairment
(24-hr creatinine clearance [CrCl] = 30 to 50 mL/min,
Cockcroft-Gault [C-G]) is 50 mg per day. The maximum recommended
dose in patients with severe renal impairment (24-hr CrCl less than
30 mL/min, C-G) or end-stage renal disease (ESRD) is 25 mg every
day or 50 mg every other day. Supplemental doses should not be
given to patients after dialysis <span class="Italics">[see
<a href="#S8.6">Use in Specific Populations (8.6)</a> and <a href=
"#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-2.2.2" id="section-2.2.2"></a>
<p class="First"><span class="Underline">Patients with hepatic
impairment</span></p>
<p>The recommended dose in patients with moderate to severe hepatic
impairment is 50 mg per day. Dose escalation above 100 mg per day
is not recommended <span class="Italics">[see <a href=
"#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S2.3" id=
"S2.3"></a> <a name="section-2.3" id="section-2.3"></a>
<h2>2.3 Maintenance/Continuation/Extended Treatment</h2>
<p class="First">It is generally agreed that acute episodes of
major depressive disorder require several months or longer of
sustained pharmacologic therapy. Longer-term efficacy of PRISTIQ
(50–400 mg) was established in two maintenance trials <span class=
"Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>.
Patients should be periodically reassessed to determine the need
for continued treatment.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S2.4" id=
"S2.4"></a> <a name="section-2.4" id="section-2.4"></a>
<h2>2.4 Discontinuing PRISTIQ</h2>
<p class="First" style="border-left:1px solid;"><span class=
"XmChange">Symptoms associated with discontinuation of PRISTIQ,
other SNRIs and SSRIs have been reported <span class="Italics">[see
<a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.
Patients should be monitored for these symptoms when discontinuing
treatment. A gradual reduction in the dose rather than abrupt
cessation is recommended whenever possible. If intolerable symptoms
occur following a decrease in the dose or upon discontinuation of
treatment, then resuming the previously prescribed dose may be
considered. Subsequently, the physician may continue decreasing the
dose, but at a more gradual rate. The 25 mg dose is available for
discontinuing therapy.</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S2.5" id=
"S2.5"></a> <a name="section-2.5" id="section-2.5"></a>
<h2>2.5 Switching Patients From Other Antidepressants to
PRISTIQ</h2>
<p class="First">Discontinuation symptoms have been reported when
switching patients from other antidepressants, including
venlafaxine, to PRISTIQ. Tapering of the initial antidepressant may
be necessary to minimize discontinuation symptoms.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S2.6" id=
"S2.6"></a> <a name="section-2.6" id="section-2.6"></a>
<h2>2.6 Switching Patients To or From a Monoamine Oxidase Inhibitor
(MAOI) Intended to Treat Psychiatric Disorders</h2>
<p class="First">At least 14 days should elapse between
discontinuation of an MAOI intended to treat psychiatric disorders
and initiation of therapy with PRISTIQ. Conversely, at least 7 days
should be allowed after stopping PRISTIQ before starting an MAOI
intended to treat psychiatric disorders [<span class="Italics">see
Contraindications (4.2)</span>].</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-2.6.1" id="section-2.6.1"></a>
<p class="First"><span class="Bold">Use of PRISTIQ with other MAOIs
such as Linezolid or Methylene Blue</span></p>
<p>Do not start PRISTIQ in a patient who is being treated with
linezolid or intravenous methylene blue because there is increased
risk of serotonin syndrome. In a patient who requires more urgent
treatment of a psychiatric condition, other interventions,
including hospitalization, should be considered <span class=
"Italics">[see Contraindications (4.2)]</span>.</p>
<p>In some cases, a patient already receiving PRISTIQ therapy may
require urgent treatment with linezolid or intravenous methylene
blue. If acceptable alternatives to linezolid or intravenous
methylene blue treatment are not available and the potential
benefits of linezolid or intravenous methylene blue treatment are
judged to outweigh the risks of serotonin syndrome in a particular
patient, PRISTIQ should be stopped promptly, and linezolid or
intravenous methylene blue can be administered. The patient should
be monitored for symptoms of serotonin syndrome for 7 days or until
24 hours after the last dose of linezolid or intravenous methylene
blue, whichever comes first. Therapy with PRISTIQ may be resumed 24
hours after the last dose of linezolid or intravenous methylene
blue <span class="Italics">[see <a href="#S5.2">Warnings and
Precautions (5.2)</a>]</span>.</p>
<p>The risk of administering methylene blue by non-intravenous
routes (such as oral tablets or by local injection) or in
intravenous doses much lower than 1 mg/kg with PRISTIQ is unclear.
The clinician should, nevertheless, be aware of the possibility of
emergent symptoms of serotonin syndrome with such use <span class=
"Italics">[see <a href="#S5.2">Warnings and Precautions
(5.2)</a>]</span>.</p>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43678-2"><a name="S3" id="S3"></a> <a name="section-3" id=
"section-3"></a>
<p class="First">PRISTIQ<span class="Sup">®</span> (desvenlafaxine)
Extended-Release Tablets are available as 25 mg, 50 mg and 100 mg
tablets.</p>
<p>25 mg, tan, square pyramid tablet debossed with "W" over "25" on
the flat side</p>
<p>50 mg, light pink, square pyramid tablet debossed with "W" over
"50" on the flat side</p>
<p>100 mg, reddish-orange, square pyramid tablet debossed with "W"
over "100" on the flat side</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">4 CONTRAINDICATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34070-3"><a name="S4" id="S4"></a> <a name="section-4" id=
"section-4"></a>
<ul>
<li>Hypersensitivity to desvenlafaxine succinate, venlafaxine
hydrochloride or to any excipients in the PRISTIQ formulation.
Angioedema has been reported in patients treated with PRISTIQ
<span class="Italics">[see <a href="#S6.1">Adverse Reactions
(6.1)</a>]</span>.</li>
<li>The use of MAOIs intended to treat psychiatric disorders with
PRISTIQ or within 7 days of stopping treatment with PRISTIQ is
contraindicated because of an increased risk of serotonin syndrome.
The use of PRISTIQ within 14 days of stopping an MAOI intended to
treat psychiatric disorders is also contraindicated <span class=
"Italics">[see <a href="#S2.6">Dosage and Administration
(2.6)</a></span> and <span class="Italics"><a href="#S5.2">Warnings
and Precautions (5.2)</a>].</span></li>
<li>Starting PRISTIQ in a patient who is being treated with MAOIs
such as linezolid or intravenous methylene blue is also
contraindicated because of an increased risk of serotonin syndrome
[see <a href="#S2.6">Dosage and Administration (2.6)</a> and
<a href="#S5.2">Warnings and Precautions (5.2)</a>].</li>
</ul>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">5 WARNINGS AND PRECAUTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43685-7"><a name="S5" id="S5"></a> <a name="section-5" id=
"section-5"></a>
<div class="Section" data-sectioncode="42229-5"><a name="S5.1" id=
"S5.1"></a> <a name="section-5.1" id="section-5.1"></a>
<h2>5.1 Suicidal Thoughts and Behaviors in Children, Adolescents
and Young Adults</h2>
<p class="First">Patients with major depressive disorder (MDD),
both adult and pediatric, may experience worsening of their
depression and/or the emergence of suicidal ideation and behavior
(suicidality) or unusual changes in behavior, whether or not they
are taking antidepressant medications, and this risk may persist
until significant remission occurs. Suicide is a known risk of
depression and certain other psychiatric disorders, and these
disorders themselves are the strongest predictors of suicide. There
has been a long-standing concern, however, that antidepressants may
have a role in inducing worsening of depression and the emergence
of suicidality in certain patients during the early phases of
treatment. Pooled analyses of short-term placebo-controlled studies
of antidepressant drugs (SSRIs and others) showed that these drugs
increase the risk of suicidal thinking and behavior (suicidality)
in children, adolescents, and young adults (ages 18 to 24) with
major depressive disorder (MDD) and other psychiatric disorders.
Short-term studies did not show an increase in the risk of
suicidality with antidepressants compared to placebo in adults
beyond age 24; there was a reduction with antidepressants compared
to placebo in adults aged 65 and older.</p>
<p>The pooled analyses of placebo-controlled studies in children
and adolescents with MDD, obsessive compulsive disorder (OCD), or
other psychiatric disorders included a total of 24 short-term
studies of 9 antidepressant drugs in over 4,400 patients. The
pooled analyses of placebo-controlled studies in adults with MDD or
other psychiatric disorders included a total of 295 short-term
studies (median duration of 2 months) of 11 antidepressant drugs in
over 77,000 patients. There was considerable variation in risk of
suicidality among drugs, but a tendency toward an increase in the
younger patients for almost all drugs studied. There were
differences in absolute risk of suicidality across the different
indications, with the highest incidence in MDD. The risk
differences (drug vs. placebo), however, were relatively stable
within age strata and across indications. These risk differences
(drug-placebo difference in the number of cases of suicidality per
1,000 patients treated) are provided in Table 1.</p>
<a name="table1" id="table1"></a>
<div class="scrollingtable">
<table width="75%">
<caption><span>Table 1</span></caption>
<colgroup>
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="80%"></colgroup>
<thead>
<tr class="First Last">
<th class="Lrule Rrule" align="center" valign="bottom">Age
Range</th>
<th class="Rrule" align="center">Drug-Placebo Difference in Number
of Cases of Suicidality per 1,000 Patients Treated</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center">Increases Compared to Placebo</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">&lt;18</td>
<td class="Rrule" align="center">14 additional cases</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">18 to 24</td>
<td class="Rrule" align="center">5 additional cases</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center">Decreases Compared to Placebo</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">25 to 64</td>
<td class="Rrule" align="center">1 fewer case</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">≥65</td>
<td class="Rrule" align="center">6 fewer cases</td>
</tr>
</tbody>
</table>
</div>
<p>No suicides occurred in any of the pediatric studies. There were
suicides in the adult studies, but the number was not sufficient to
reach any conclusion about drug effect on suicide.</p>
<p>It is unknown whether the suicidality risk extends to
longer-term use, i.e., beyond several months. However, there is
substantial evidence from placebo-controlled maintenance studies in
adults with depression that the use of antidepressants can delay
the recurrence of depression.</p>
<p><span class="Bold">All patients being treated with
antidepressants for any indication should be monitored
appropriately and observed closely for clinical worsening,
suicidality, and unusual changes in behavior, especially during the
initial few months of a course of drug therapy, or at times of dose
changes, either increases or decreases.</span></p>
<p>The following symptoms, anxiety, agitation, panic attacks,
insomnia, irritability, hostility, aggressiveness, impulsivity,
akathisia (psychomotor restlessness), hypomania, and mania, have
been reported in adult and pediatric patients being treated with
antidepressants for major depressive disorder as well as for other
indications, both psychiatric and nonpsychiatric. Although a causal
link between the emergence of such symptoms and either the
worsening of depression and/or the emergence of suicidal impulses
has not been established, there is concern that such symptoms may
represent precursors to emerging suicidality.</p>
<p>Consideration should be given to changing the therapeutic
regimen, including possibly discontinuing the medication, in
patients whose depression is persistently worse, or who are
experiencing emergent suicidality or symptoms that might be
precursors to worsening depression or suicidality, especially if
these symptoms are severe, abrupt in onset, or were not part of the
patient's presenting symptoms.</p>
<p>If the decision has been made to discontinue treatment,
medication should be tapered, as rapidly as is feasible, but with
recognition that abrupt discontinuation can be associated with
certain symptoms <span class="Italics">[see <a href="#S2.4">Dosage
and Administration (2.4)</a> and <a href="#S5.7">Warnings and
Precautions (5.7)</a> for a description of the risks of
discontinuation of PRISTIQ]</span>.</p>
<p><span class="Bold">Families and caregivers of patients being
treated with antidepressants for major depressive disorder or other
indications, both psychiatric and nonpsychiatric, should be alerted
about the need to monitor patients for the emergence of agitation,
irritability, unusual changes in behavior, and the other symptoms
described above, as well as the emergence of suicidality, and to
report such symptoms immediately to healthcare providers. Such
monitoring should include daily observation by families and
caregivers</span>.</p>
<p>Prescriptions for PRISTIQ should be written for the smallest
quantity of tablets consistent with good patient management, in
order to reduce the risk of overdose.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-5.1.1" id="section-5.1.1"></a>
<p class="First"><span class="Underline">Screening patients for
bipolar disorder</span></p>
<p>A major depressive episode may be the initial presentation of
bipolar disorder. It is generally believed (though not established
in controlled studies) that treating such an episode with an
antidepressant alone may increase the likelihood of precipitation
of a mixed/manic episode in patients at risk for bipolar disorder.
Whether any of the symptoms described above represent such a
conversion is unknown. However, prior to initiating treatment with
an antidepressant, patients with depressive symptoms should be
adequately screened to determine if they are at risk for bipolar
disorder; such screening should include a detailed psychiatric
history, including a family history of suicide, bipolar disorder,
and depression. It should be noted that PRISTIQ is not approved for
use in treating bipolar depression.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.2" id=
"S5.2"></a> <a name="section-5.2" id="section-5.2"></a>
<h2>5.2 Serotonin Syndrome</h2>
<p class="First">The development of a potentially life-threatening
serotonin syndrome has been reported with SNRIs and SSRIs,
including PRISTIQ, alone but particularly with concomitant use of
other serotonergic drugs (including triptans, tricyclic
antidepressants, fentanyl, lithium, tramadol, tryptophan,
buspirone, and St. John's Wort), and with drugs that impair
metabolism of serotonin (in particular, MAOIs, both those intended
to treat psychiatric disorders and also others, such as linezolid
and intravenous methylene blue).</p>
<p>Serotonin syndrome symptoms may include mental status changes
(e.g., agitation, hallucinations, delirium, and coma), autonomic
instability (e.g., tachycardia, labile blood pressure, dizziness,
diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g.,
tremor, rigidity, myoclonus, hyperreflexia, incoordination),
seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting,
diarrhea). Patients should be monitored for the emergence of
serotonin syndrome.</p>
<p>The concomitant use of PRISTIQ with MAOIs intended to treat
psychiatric disorders is contraindicated. PRISTIQ should also not
be started in a patient who is being treated with MAOIs such as
linezolid or intravenous methylene blue. All reports with methylene
blue that provided information on the route of administration
involved intravenous administration in the dose range of 1 mg/kg to
8 mg/kg. No reports involved the administration of methylene blue
by other routes (such as oral tablets or local tissue injection) or
at lower doses. There may be circumstances when it is necessary to
initiate treatment with a MAOI such as linezolid or intravenous
methylene blue in a patient taking PRISTIQ. PRISTIQ should be
discontinued before initiating treatment with the MAOI <span class=
"Italics">[see Contraindications (4.2)</span> and <span class=
"Italics"><a href="#S2.6">Dosage and Administration
(2.6)</a>]</span>.</p>
<p>If concomitant use of PRISTIQ with other serotonergic drugs,
including triptans, tricyclic antidepressants, fentanyl, lithium,
tramadol, buspirone, tryptophan, and St. John's Wort is clinically
warranted, patients should be made aware of a potential increased
risk for serotonin syndrome, particularly during treatment
initiation and dose increases.</p>
<p>Treatment with PRISTIQ and any concomitant serotonergic agents
should be discontinued immediately if the above events occur and
supportive symptomatic treatment should be initiated.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.3" id=
"S5.3"></a> <a name="section-5.3" id="section-5.3"></a>
<h2>5.3 Elevated Blood Pressure</h2>
<p class="First">Patients receiving PRISTIQ should have regular
monitoring of blood pressure since increases in blood pressure were
observed in clinical studies <span class="Italics">[see <a href=
"#S6.1">Adverse Reactions (6.1)</a>]</span>. Pre-existing
hypertension should be controlled before initiating treatment with
PRISTIQ. Caution should be exercised in treating patients with
pre-existing hypertension, cardiovascular, or cerebrovascular
conditions that might be compromised by increases in blood
pressure. Cases of elevated blood pressure requiring immediate
treatment have been reported with PRISTIQ.</p>
<p>Sustained blood pressure increases could have adverse
consequences. For patients who experience a sustained increase in
blood pressure while receiving PRISTIQ, either dose reduction or
discontinuation should be considered <span class="Italics">[see
<a href="#S6.1">Adverse Reactions (6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.4" id=
"S5.4"></a> <a name="section-5.4" id="section-5.4"></a>
<h2>5.4 Abnormal Bleeding</h2>
<p class="First">SSRIs and SNRIs, including PRISTIQ, may increase
the risk of bleeding events. Concomitant use of aspirin,
nonsteroidal anti-inflammatory drugs, warfarin, and other
anticoagulants may add to this risk. Case reports and
epidemiological studies (case-control and cohort design) have
demonstrated an association between use of drugs that interfere
with serotonin reuptake and the occurrence of gastrointestinal
bleeding. Bleeding events related to SSRIs and SNRIs have ranged
from ecchymosis, hematoma, epistaxis, and petechiae to
life-threatening hemorrhages. Patients should be cautioned about
the risk of bleeding associated with the concomitant use of PRISTIQ
and NSAIDs, aspirin, or other drugs that affect coagulation or
bleeding.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.5" id=
"S5.5"></a> <a name="section-5.5" id="section-5.5"></a>
<h2>5.5 Angle Closure Glaucoma</h2>
<p class="First" style="border-left:1px solid;"><span class=
"XmChange">Angle-Closure Glaucoma: The pupillary dilation that
occurs following use of many antidepressant drugs including Pristiq
may trigger an angle closure attack in a patient with anatomically
narrow angles who does not have a patent iridectomy.</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.6" id=
"S5.6"></a> <a name="section-5.6" id="section-5.6"></a>
<h2>5.6 Activation of Mania/Hypomania</h2>
<p class="First">During all MDD phase 2 and phase 3 studies, mania
was reported for approximately 0.02% of patients treated with
PRISTIQ. Activation of mania/hypomania has also been reported in a
small proportion of patients with major affective disorder who were
treated with other marketed antidepressants. As with all
antidepressants, PRISTIQ should be used cautiously in patients with
a history or family history of mania or hypomania.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.7" id=
"S5.7"></a> <a name="section-5.7" id="section-5.7"></a>
<h2>5.7 Discontinuation Syndrome</h2>
<p class="First">Discontinuation symptoms have been systematically
and prospectively evaluated in patients treated with PRISTIQ during
clinical studies in Major Depressive Disorder. Abrupt
discontinuation or dose reduction has been associated with the
appearance of new symptoms that include dizziness, nausea,
headache, irritability, insomnia, diarrhea, anxiety, fatigue,
abnormal dreams, and hyperhidrosis. In general, discontinuation
events occurred more frequently with longer duration of
therapy.</p>
<p>During marketing of SNRIs (Serotonin and Norepinephrine Reuptake
Inhibitors), and SSRIs (Selective Serotonin Reuptake Inhibitors),
there have been spontaneous reports of adverse events occurring
upon discontinuation of these drugs, particularly when abrupt,
including the following: dysphoric mood, irritability, agitation,
dizziness, sensory disturbances (e.g., paresthesia, such as
electric shock sensations), anxiety, confusion, headache, lethargy,
emotional lability, insomnia, hypomania, tinnitus, and seizures.
While these events are generally self-limiting, there have been
reports of serious discontinuation symptoms.</p>
<p>Patients should be monitored for these symptoms when
discontinuing treatment with PRISTIQ. A gradual reduction in the
dose rather than abrupt cessation is recommended whenever possible.
If intolerable symptoms occur following a decrease in the dose or
upon discontinuation of treatment, then resuming the previously
prescribed dose may be considered. Subsequently, the physician may
continue decreasing the dose, but at a more gradual rate
<span class="Italics">[see <a href="#S2.4">Dosage and
Administration (2.4)</a> and <a href="#S6.1">Adverse Reactions
(6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.8" id=
"S5.8"></a> <a name="section-5.8" id="section-5.8"></a>
<h2>5.8 Seizure</h2>
<p class="First">Cases of seizure have been reported in
pre-marketing clinical studies with PRISTIQ. PRISTIQ has not been
systematically evaluated in patients with a seizure disorder.
Patients with a history of seizures were excluded from
pre-marketing clinical studies. PRISTIQ should be prescribed with
caution in patients with a seizure disorder.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.9" id=
"S5.9"></a> <a name="section-5.9" id="section-5.9"></a>
<h2>5.9 Hyponatremia</h2>
<p class="First">Hyponatremia may occur as a result of treatment
with SSRIs and SNRIs, including PRISTIQ. In many cases, this
hyponatremia appears to be the result of the syndrome of
inappropriate antidiuretic hormone secretion (SIADH). Cases with
serum sodium lower than 110 mmol/L have been reported. Elderly
patients may be at greater risk of developing hyponatremia with
SSRIs and SNRIs. Also, patients taking diuretics or who are
otherwise volume depleted can be at greater risk <span class=
"Italics">[see <a href="#S8.5">Use in Specific Populations
(8.5)</a> and Clinical Pharmacology (12.6)]</span>. Discontinuation
of PRISTIQ should be considered in patients with symptomatic
hyponatremia and appropriate medical intervention should be
instituted.</p>
<p>Signs and symptoms of hyponatremia include headache, difficulty
concentrating, memory impairment, confusion, weakness, and
unsteadiness, which can lead to falls. Signs and symptoms
associated with more severe and/or acute cases have included
hallucination, syncope, seizure, coma, respiratory arrest, and
death.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S5.10" id=
"S5.10"></a> <a name="section-5.10" id="section-5.10"></a>
<h2>5.10 Interstitial Lung Disease and Eosinophilic Pneumonia</h2>
<p class="First">Interstitial lung disease and eosinophilic
pneumonia associated with venlafaxine (the parent drug of PRISTIQ)
therapy have been rarely reported. The possibility of these adverse
events should be considered in patients treated with PRISTIQ who
present with progressive dyspnea, cough, or chest discomfort. Such
patients should undergo a prompt medical evaluation, and
discontinuation of PRISTIQ should be considered.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">6 ADVERSE REACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34084-4"><a name="S6" id="S6"></a> <a name="section-6" id=
"section-6"></a>
<p class="First">The following adverse reactions are discussed in
greater detail in other sections of the label.</p>
<ul>
<li>Hypersensitivity <span class="Italics">[see <a href=
"#S4">Contraindications (4)</a>]</span></li>
<li>Suicidal Thoughts and Behaviors in Adolescents and Young Adults
<span class="Italics">[see <a href="#S5.1">Warnings and Precautions
(5.1)</a>]</span></li>
<li>Serotonin Syndrome <span class="Italics">[see <a href=
"#S5.2">Warnings and Precautions (5.2)</a>]</span></li>
<li>Elevated Blood Pressure <span class="Italics">[see <a href=
"#S5.3">Warnings and Precautions (5.3)</a>]</span></li>
<li>Abnormal Bleeding <span class="Italics">[see <a href=
"#S5.4">Warnings and Precautions (5.4)</a>]</span></li>
<li>Angle Closure Glaucoma [<span class="Italics">see <a href=
"#S5.5">Warnings and Precautions (5.5)</a>]</span></li>
<li>Activation of Mania/Hypomania <span class="Italics">[see
<a href="#S5.6">Warnings and Precautions (5.6)</a>]</span></li>
<li>Discontinuation Syndrome <span class="Italics">[see <a href=
"#S5.7">Warnings and Precautions (5.7)</a>]</span></li>
<li>Seizure <span class="Italics">[see <a href="#S5.8">Warnings and
Precautions (5.8)</a>]</span></li>
<li>Hyponatremia <span class="Italics">[see <a href=
"#S5.9">Warnings and Precautions (5.9)</a>]</span></li>
<li>Interstitial Lung Disease and Eosinophilic Pneumonia
<span class="Italics">[see <a href="#S5.10">Warnings and
Precautions (5.10)</a>]</span></li>
</ul>
<div class="Section" data-sectioncode="42229-5"><a name="S6.1" id=
"S6.1"></a> <a name="section-6.1" id="section-6.1"></a>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely
varying conditions, adverse reaction rates observed in the clinical
trials of a drug cannot be directly compared to rates in the
clinical studies of another drug and may not reflect the rates
observed in clinical practice.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-6.1.1" id="section-6.1.1"></a>
<p class="First"><span class="Underline">Patient
exposure</span></p>
<p>PRISTIQ was evaluated for safety in 8,394 patients diagnosed
with major depressive disorder who participated in multiple-dose
pre-marketing studies, representing 2,784 patient-years of
exposure. Of the total 8,394 patients exposed to at least one dose
of PRISTIQ; 2,116 were exposed to PRISTIQ for 6 months,
representing 1,658 patient-years of exposure, and 421 were exposed
for one year, representing 416 patient-years of exposure.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-6.1.2" id="section-6.1.2"></a>
<p class="First"><span class="Underline">Adverse reactions reported
as reasons for discontinuation of treatment</span></p>
<p>In the pre-marketing pooled 8-week placebo-controlled studies in
patients with MDD, 1,834 patients were exposed to PRISTIQ (50 to
400 mg). Of the 1,834 patients, 12% discontinued treatment due to
an adverse reaction, compared with 3% of the 1,116 placebo-treated
patients. At the recommended dose of 50 mg, the discontinuation
rate due to an adverse reaction for PRISTIQ (4.1%) was similar to
the rate for placebo (3.8%). For the 100 mg dose of PRISTIQ the
discontinuation rate due to an adverse reaction was 8.7%.</p>
<p>The most common adverse reactions leading to discontinuation in
at least 2% and at a rate greater than placebo of the PRISTIQ
treated patients in the short-term studies, up to 8 weeks, were:
nausea (4%); dizziness, headache and vomiting (2% each). In a
longer-term study, up to 9 months, the most common was vomiting
(2%).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-6.1.3" id="section-6.1.3"></a>
<p class="First"><span class="Underline">Common adverse reactions
in placebo-controlled MDD studies</span></p>
<p>The most commonly observed adverse reactions in PRISTIQ treated
MDD patients in pre-marketing pooled 8-week, placebo-controlled,
fixed-dose studies (incidence ≥ 5% and at least twice the rate of
placebo in the 50 or 100 mg dose groups) were: nausea, dizziness,
insomnia, hyperhidrosis, constipation, somnolence, decreased
appetite, anxiety, and specific male sexual function disorders.</p>
<p>Table 2 shows the incidence of common adverse reactions that
occurred in ≥ 2% of PRISTIQ treated MDD patients and twice the rate
of placebo at any dose in the pre-marketing pooled 8-week,
placebo-controlled, fixed dose clinical studies</p>
<a name="table2" id="table2"></a>
<div class="scrollingtable">
<table width="90%">
<caption><span>Table 2: Common Adverse Reactions (≥ 2% in any
Fixed-Dose Group and Twice the Rate of Placebo) in Pre-marketing
Pooled MDD 8-Week Placebo-Controlled Studies</span></caption>
<colgroup>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%"></colgroup>
<thead>
<tr class="Botrule First">
<th align="left"></th>
<th align="center" colspan="5">Percentage of Patients Reporting
Reaction</th>
</tr>
<tr>
<th align="left"></th>
<th align="center"></th>
<th class="Botrule" align="center" colspan="4">PRISTIQ</th>
</tr>
<tr class="Last">
<th align="left">System Organ Class<br>
Preferred Term</th>
<th align="center">Placebo<br>
(n=636)</th>
<th align="center">50 mg<br>
(n=317)</th>
<th align="center">100 mg<br>
(n=424)</th>
<th align="center">200 mg<br>
(n=307)</th>
<th align="center">400 mg<br>
(n=317)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left" colspan="6"><span class="Bold">Cardiac
disorders</span></td>
</tr>
<tr>
<td align="left">Blood pressure increased</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left" colspan="6"><span class="Bold">Gastrointestinal
disorders</span></td>
</tr>
<tr>
<td align="left">Nausea</td>
<td align="center">10</td>
<td align="center">22</td>
<td align="center">26</td>
<td align="center">36</td>
<td align="center">41</td>
</tr>
<tr>
<td align="left">Dry mouth</td>
<td align="center">9</td>
<td align="center">11</td>
<td align="center">17</td>
<td align="center">21</td>
<td align="center">25</td>
</tr>
<tr>
<td align="left">Constipation</td>
<td align="center">4</td>
<td align="center">9</td>
<td align="center">9</td>
<td align="center">10</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">Vomiting</td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">6</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left" colspan="6"><span class="Bold">General disorders
and administration site conditions</span></td>
</tr>
<tr>
<td align="left">Fatigue</td>
<td align="center">4</td>
<td align="center">7</td>
<td align="center">7</td>
<td align="center">10</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">Chills</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">&lt;1</td>
<td align="center">3</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">Feeling jittery</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left" colspan="6"><span class="Bold">Metabolism and
nutrition disorders</span></td>
</tr>
<tr>
<td align="left">Decreased appetite</td>
<td align="center">2</td>
<td align="center">5</td>
<td align="center">8</td>
<td align="center">10</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left" colspan="6"><span class="Bold">Nervous system
disorders</span></td>
</tr>
<tr>
<td align="left">Dizziness</td>
<td align="center">5</td>
<td align="center">13</td>
<td align="center">10</td>
<td align="center">15</td>
<td align="center">16</td>
</tr>
<tr>
<td align="left">Somnolence</td>
<td align="center">4</td>
<td align="center">4</td>
<td align="center">9</td>
<td align="center">12</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">Tremor</td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">9</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">Disturbance in attention</td>
<td align="center">&lt;1</td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left" colspan="6"><span class="Bold">Psychiatric
disorders</span></td>
</tr>
<tr>
<td align="left">Insomnia</td>
<td align="center">6</td>
<td align="center">9</td>
<td align="center">12</td>
<td align="center">14</td>
<td align="center">15</td>
</tr>
<tr>
<td align="left">Anxiety</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">5</td>
<td align="center">4</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">Nervousness</td>
<td align="center">1</td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">Abnormal dreams</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left" colspan="6"><span class="Bold">Renal and urinary
disorders</span></td>
</tr>
<tr class="Botrule">
<td align="left">Urinary hesitation</td>
<td align="center">0</td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left" colspan="6"><span class="Bold">Respiratory,
thoracic and mediastinal disorders</span></td>
</tr>
<tr>
<td align="left">Yawning</td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">4</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left" colspan="6"><span class="Bold">Skin and
subcutaneous tissue disorders</span></td>
</tr>
<tr>
<td align="left">Hyperhidrosis</td>
<td align="center">4</td>
<td align="center">10</td>
<td align="center">11</td>
<td align="center">18</td>
<td align="center">21</td>
</tr>
<tr>
<td align="left" colspan="6"><span class="Bold">Special
Senses</span></td>
</tr>
<tr>
<td align="left">Vision blurred</td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">4</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">Mydriasis</td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">6</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">Vertigo</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">5</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">Tinnitus</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">Dysgeusia</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left" colspan="6"><span class="Bold">Vascular
disorders</span></td>
</tr>
<tr class="Last">
<td align="left">Hot flush</td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-6.1.4" id="section-6.1.4"></a>
<p class="First"><span class="Underline">Sexual function adverse
reactions</span></p>
<p>Table 3 shows the incidence of sexual function adverse reactions
that occurred in ≥ 2% of PRISTIQ treated MDD patients in any
fixed-dose group (pre-marketing pooled 8-week, placebo-controlled,
fixed -dose, clinical studies).</p>
<a name="table3" id="table3"></a>
<div class="scrollingtable">
<table width="90%">
<caption><span>Table 3: Sexual Function Adverse Reactions (≥ 2% in
Men or Women in any PRISTIQ Group) During the On-Therapy
Period</span></caption>
<colgroup>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%"></colgroup>
<tbody class="Headless">
<tr class="First">
<td align="left"></td>
<td align="center"></td>
<td class="Botrule" align="center" colspan="4"><span class=
"Bold">PRISTIQ</span></td>
</tr>
<tr class="Botrule">
<td align="left"></td>
<td align="center"><span class="Bold">Placebo</span><br>
(n=239)</td>
<td align="center"><span class="Bold">50 mg</span><br>
(n=108)</td>
<td align="center"><span class="Bold">100 mg</span><br>
(n=157)</td>
<td align="center"><span class="Bold">200 mg</span><br>
(n=131)</td>
<td align="center"><span class="Bold">400 mg</span><br>
(n=154)</td>
</tr>
<tr>
<td align="left" colspan="6"><span class="Bold Italics">Men
only</span></td>
</tr>
<tr>
<td align="left">Anorgasmia</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">5</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">Libido decreased</td>
<td align="center">1</td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">6</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">Orgasm abnormal</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">Ejaculation delayed</td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">5</td>
<td align="center">7</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">Erectile dysfunction</td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">6</td>
<td align="center">8</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">Ejaculation disorder</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">Ejaculation failure</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">Sexual dysfunction</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"></td>
<td align="center"></td>
<td class="Botrule" align="center" colspan="4"><span class=
"Bold">PRISTIQ</span></td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Placebo</span><br>
(n=397)</td>
<td align="center"><span class="Bold">50 mg</span><br>
(n=209)</td>
<td align="center"><span class="Bold">100 mg</span><br>
(n=267)</td>
<td align="center"><span class="Bold">200 mg</span><br>
(n=176)</td>
<td align="center"><span class="Bold">400 mg</span><br>
(n=163)</td>
</tr>
<tr>
<td align="left" colspan="6"><span class="Bold Italics">Women
only</span></td>
</tr>
<tr class="Last">
<td align="left">Anorgasmia</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-6.1.5" id="section-6.1.5"></a>
<p class="First"><span class="Underline">Other adverse reactions
observed in premarketing and postmarketing clinical
studies</span></p>
<p>Other infrequent adverse reactions, not described elsewhere in
the label, occurring at an incidence of &lt; 2% in MDD patients
treated with PRISTIQ were:</p>
<p><span class="Bold Italics">Cardiac disorders</span> –
Tachycardia.</p>
<p><span class="Bold Italics">General disorders and administration
site conditions</span> – Asthenia.</p>
<p><span class="Bold Italics">Investigations –</span> Weight
increased, liver function test abnormal, blood prolactin
increased.</p>
<p><span class="Bold Italics">Musculoskeletal and connective tissue
disorders –</span> Musculoskeletal stiffness.</p>
<p><span class="Bold Italics">Nervous system disorders
–</span>Syncope, convulsion, dystonia.</p>
<p><span class="Bold Italics">Psychiatric disorders –</span>
Depersonalization, bruxism.</p>
<p><span class="Bold Italics">Renal and urinary disorders</span> –
Urinary retention.</p>
<p><span class="Bold Italics">Skin and subcutaneous tissue
disorders</span> <span class="Bold">–</span> Rash, alopecia,
photosensitivity reaction, angioedema.</p>
<p>In clinical studies, there were uncommon reports of ischemic
cardiac adverse reactions, including myocardial ischemia,
myocardial infarction, and coronary occlusion requiring
revascularization; these patients had multiple underlying cardiac
risk factors. More patients experienced these events during PRISTIQ
treatment as compared to placebo.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-6.1.5.1" id="section-6.1.5.1"></a>
<p class="First"><span class="Bold Underline">Laboratory, ECG and
vital sign changes observed in MDD clinical studies</span></p>
<p>The following changes were observed in pre-marketing
placebo-controlled, short-term MDD studies with PRISTIQ.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-6.1.5.1.1" id="section-6.1.5.1.1"></a>
<p class="First"><span class="Bold Italics">Lipids</span></p>
<p>Elevations in fasting serum total cholesterol, LDL (low density
lipoproteins) cholesterol, and triglycerides occurred in the
controlled studies. Some of these abnormalities were considered
potentially clinically significant.</p>
<p>The percentage of patients who exceeded a predetermined
threshold value is shown in Table 4.</p>
<a name="table4" id="table4"></a>
<div class="scrollingtable">
<table width="80%">
<caption><span>Table 4: Incidence (%) of Patients With Lipid
Abnormalities of Potential Clinical Significance*</span></caption>
<colgroup>
<col align="left" valign="top" width="35%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%"></colgroup>
<thead>
<tr class="First">
<th align="left"></th>
<th align="center"></th>
<th class="Botrule" align="center" colspan="4">PRISTIQ</th>
</tr>
<tr class="Last">
<th align="left"></th>
<th align="center">Placebo</th>
<th align="center">50 mg</th>
<th align="center">100 mg</th>
<th align="center">200 mg</th>
<th align="center">400 mg</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">Total Cholesterol<br>
*(Increase of ≥ 50 mg/dl and an absolute value of ≥ 261 mg/dl)</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">4</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left">LDL Cholesterol<br>
*(Increase ≥ 50 mg/dl and an absolute value of ≥ 190 mg/dl)</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr class="Botrule Last">
<td align="left">Triglycerides, fasting<br>
*(Fasting: ≥ 327 mg/dl)</td>
<td align="center">3</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">4</td>
<td align="center">6</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-6.1.5.1.2" id="section-6.1.5.1.2"></a>
<p class="First"><span class="Bold Italics">Proteinuria</span></p>
<p>Proteinuria, greater than or equal to trace, was observed in the
pre-marketing fixed-dose controlled studies (see <a href=
"#table5">Table 5</a>). This proteinuria was not associated with
increases in BUN or creatinine and was generally transient.</p>
<a name="table5" id="table5"></a>
<div class="scrollingtable">
<table width="80%">
<caption><span>Table 5: Incidence (%) of Patients with Proteinuria
in the Fixed-dose Clinical Studies</span></caption>
<colgroup>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%"></colgroup>
<thead>
<tr class="First">
<th align="left"></th>
<th align="center"></th>
<th class="Botrule" align="center" colspan="4">PRISTIQ</th>
</tr>
<tr class="Last">
<th align="left"></th>
<th align="center">Placebo</th>
<th align="center">50 mg</th>
<th align="center">100 mg</th>
<th align="center">200 mg</th>
<th align="center">400 mg</th>
</tr>
</thead>
<tbody>
<tr class="First Last">
<td align="left">Proteinuria</td>
<td align="center">4</td>
<td align="center">6</td>
<td align="center">8</td>
<td align="center">5</td>
<td align="center">7</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-6.1.5.1.3" id="section-6.1.5.1.3"></a>
<p class="First"><span class="Bold Italics">Vital sign
changes</span></p>
<p>Table 6 summarizes the changes that were observed in
placebo-controlled, short-term, pre-marketing studies with PRISTIQ
in patients with MDD (doses 50 to 400 mg).</p>
<a name="table6" id="table6"></a>
<div class="scrollingtable">
<table width="80%">
<caption><span>Table 6: Mean Changes in Vital Signs at Final on
Therapy for All Short-term, Fixed-dose Controlled
Studies</span></caption>
<colgroup>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%"></colgroup>
<thead>
<tr class="First">
<th align="left"></th>
<th align="center"></th>
<th class="Botrule" align="center" colspan="4">PRISTIQ</th>
</tr>
<tr class="Botrule Last">
<th align="left"></th>
<th align="center">Placebo</th>
<th align="center">50 mg</th>
<th align="center">100 mg</th>
<th align="center">200 mg</th>
<th align="center">400 mg</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left" colspan="6"><span class="Bold">Blood
pressure</span></td>
</tr>
<tr>
<td align="left">Supine systolic bp (mm Hg)</td>
<td align="center">-1.4</td>
<td align="center">1.2</td>
<td align="center">2.0</td>
<td align="center">2.5</td>
<td align="center">2.1</td>
</tr>
<tr>
<td align="left">Supine diastolic bp (mm Hg)</td>
<td align="center">-0.6</td>
<td align="center">0.7</td>
<td align="center">0.8</td>
<td align="center">1.8</td>
<td align="center">2.3</td>
</tr>
<tr>
<td align="left" colspan="6"><span class="Bold">Pulse
rate</span></td>
</tr>
<tr>
<td align="left">Supine pulse (bpm)</td>
<td align="center">-0.3</td>
<td align="center">1.3</td>
<td align="center">1.3</td>
<td align="center">0.9</td>
<td align="center">4.1</td>
</tr>
<tr class="Last">
<td align="left"><span class="Bold">Weight (kg)</span></td>
<td align="center">0.0</td>
<td align="center">-0.4</td>
<td align="center">-0.6</td>
<td align="center">-0.9</td>
<td align="center">-1.1</td>
</tr>
</tbody>
</table>
</div>
<p>Treatment with PRISTIQ at all doses from 50 mg per day to 400 mg
per day in controlled studies was associated with sustained
hypertension, defined as treatment-emergent supine diastolic blood
pressure (SDBP) ≥90 mm Hg and ≥10 mm Hg above baseline for 3
consecutive on-therapy visits (see <a href="#table7">Table 7</a>).
Analyses of patients in PRISTIQ pre-marketing short-term controlled
studies who met criteria for sustained hypertension revealed a
consistent increase in the proportion of patients who developed
sustained hypertension. This was seen at all doses with a
suggestion of a higher rate at 400 mg per day.</p>
<a name="table7" id="table7"></a>
<div class="scrollingtable">
<table width="80%">
<caption><span>Table 7: Proportion of Patients with Sustained
Elevation of Supine Diastolic Blood Pressure</span></caption>
<colgroup>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="60%"></colgroup>
<thead>
<tr class="First Last">
<th align="left">Treatment Group</th>
<th align="center">Proportion of Patients with Sustained
Hypertension</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">Placebo</td>
<td align="center">0.5%</td>
</tr>
<tr>
<td align="left">PRISTIQ 50 mg per day</td>
<td align="center">1.3%</td>
</tr>
<tr>
<td align="left">PRISTIQ 100 mg per day</td>
<td align="center">0.7%</td>
</tr>
<tr>
<td align="left">PRISTIQ 200 mg per day</td>
<td align="center">1.1%</td>
</tr>
<tr class="Last">
<td align="left">PRISTIQ 400 mg per day</td>
<td align="center">2.3%</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-6.1.5.1.4" id="section-6.1.5.1.4"></a>
<p class="First"><span class="Bold Italics">Orthostatic
hypotension</span></p>
<p>In the pre-marketing short-term, placebo-controlled clinical
studies with doses of 50 to 400 mg, systolic orthostatic
hypotension (decrease ≥30 mm Hg from supine to standing position)
occurred more frequently in patients ≥65 years of age receiving
PRISTIQ (8%, 7/87) versus placebo (2.5%, 1/40), compared to
patients &lt;65 years of age receiving PRISTIQ (0.9%, 18/1,937)
versus placebo (0.7%, 8/1,218).</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S6.2" id=
"S6.2"></a> <a name="section-6.2" id="section-6.2"></a>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reaction has been identified
during post-approval use of PRISTIQ. Because these reactions are
reported voluntarily from a population of uncertain size, it is not
always possible to reliably estimate their frequency or establish a
causal relationship to drug exposure:</p>
<p><span class="Bold Italics">Skin and subcutaneous tissue
disorders</span> – Stevens-Johnson syndrome.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">7 DRUG INTERACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34073-7"><a name="S7" id="S7"></a> <a name="section-7" id=
"section-7"></a>
<div class="Section" data-sectioncode="42229-5"><a name="S7.1" id=
"S7.1"></a> <a name="section-7.1" id="section-7.1"></a>
<h2>7.1 Monoamine Oxidase Inhibitors (MAOI)</h2>
<p class="First">Do not use MAOIs intended to treat psychiatric
disorders with desvenlafaxine or within 7 days of stopping
treatment with desvenlafaxine. Do not use desvenlafaxine within 14
days of stopping an MAOI intended to treat psychiatric disorders.
In addition, do not start desvenlafaxine in a patient who is being
treated with linezolid or intravenous methylene blue <span class=
"Italics">[see <a href="#S2.6">Dosage and Administration (2.6
)</a>, <a href="#S4">Contraindications (4)</a> and <a href=
"#S5.2">Warnings and Precautions (5.2)</a>].</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S7.2" id=
"S7.2"></a> <a name="section-7.2" id="section-7.2"></a>
<h2>7.2 Serotonergic Drugs</h2>
<p class="First">Based on the mechanism of action of desvenlafaxine
and the potential for serotonin syndrome, caution is advised when
desvenlafaxine is co-administered with other drugs that may affect
the serotonergic neurotransmitter systems <span class=
"Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a>,
<a href="#S4">Contraindications (4)</a> and <a href=
"#S5.2">Warnings and Precautions (5.2)</a>].</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S7.3" id=
"S7.3"></a> <a name="section-7.3" id="section-7.3"></a>
<h2>7.3 Drugs that Interfere with Hemostasis (e.g., NSAIDs,
Aspirin, and Warfarin)</h2>
<p class="First">Serotonin release by platelets plays an important
role in hemostasis. Epidemiological studies of case-control and
cohort design that have demonstrated an association between use of
psychotropic drugs that interfere with serotonin reuptake and the
occurrence of upper gastrointestinal bleeding. These studies have
also shown that concurrent use of an NSAID or aspirin may
potentiate this risk of bleeding. Altered anticoagulant effects,
including increased bleeding, have been reported when SSRIs and
SNRIs are co-administered with warfarin. Patients receiving
warfarin therapy should be carefully monitored when PRISTIQ is
initiated or discontinued <span class="Italics">[see <a href=
"#S5.4">Warnings and Precautions (5.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S7.4" id=
"S7.4"></a> <a name="section-7.4" id="section-7.4"></a>
<h2>7.4 Potential for Other Drugs to Affect Desvenlafaxine</h2>
<p class="First">Based on <span class="Italics">in vitro</span>
data, no dose adjustment is required for PRISTIQ when used
concomitantly with inhibitors of CYP3A4 and CYP1A1, 1A2, 2A6, 2D6,
2C8, 2C9, 2C19, 2E1, and the P-glycoprotein transporter. Clinical
studies have demonstrated no clinically significant pharmacokinetic
interaction between PRISTIQ and strong CYP 3A4 inhibitors (Figure
1).</p>
<p><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-01.jpg"
alt="Figure 1"></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S7.5" id=
"S7.5"></a> <a name="section-7.5" id="section-7.5"></a>
<h2>7.5 Potential for Desvenlafaxine to Affect Other Drugs</h2>
<p class="First">Clinical studies have shown that desvenlafaxine
does not have a clinically relevant effect on CYP2D6 metabolism at
the dose of 100 mg daily (Figure 2). Substrates primarily
metabolized by CYP2D6 (e.g., desipramine , atomoxetine,
dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine)
should be dosed at the original level when co-administered with
PRISTIQ 100 mg or lower or when PRISTIQ is discontinued. Reduce the
dose of these substrates by up to one-half if co-administered with
400 mg of PRISTIQ.</p>
<p>No additional dose adjustment is required for concomitant use of
substrates of CYP3A4, 1A2, 2A6, 2C8, 2C9, and 2C19 isozymes, and
P-glycoprotein transporter. Clinical studies have demonstrated no
clinically significant pharmacokinetic interaction between PRISTIQ
and CYP3A4 substrates (Figure 2).</p>
<p>Clinical studies have shown that desvenlafaxine (100 mg daily)
does not have a clinically relevant effect on tamoxifen and
aripiprazole, compounds that are metabolized by a combination of
both CYP2D6 and CYP3A4 enzymes (Figure 2).</p>
<p><span class="Italics">In vitro</span> studies showed minimal
inhibitory effect of desvenlafaxine on the CYP2D6 isoenzyme.</p>
<p><span class="Italics">In vitro</span>, desvenlafaxine does not
inhibit or induce the CYP3A4 isozyme.</p>
<p><span class="Italics">In vitro</span>, desvenlafaxine does not
inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19, isozymes, and
P-glycoprotein transporter and would not be expected to affect the
pharmacokinetics of drugs that are substrates of these CYP isozymes
and transporter.</p>
<p><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-02.jpg"
alt="Figure 2"></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S7.6" id=
"S7.6"></a> <a name="section-7.6" id="section-7.6"></a>
<h2>7.6 Other Drugs Containing Desvenlafaxine or Venlafaxine</h2>
<p class="First">Avoid use of PRISTIQ with other
desvenlafaxine-containing products or venlafaxine products. The
concomitant use of PRISTIQ with other desvenlafaxine-containing
products or venlafaxine will increase desvenlafaxine blood levels
and increase dose-related adverse reactions <span class=
"Italics">[see <a href="#S6">Adverse Reactions (6)</a>].</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S7.7" id=
"S7.7"></a> <a name="section-7.7" id="section-7.7"></a>
<h2>7.7 Ethanol</h2>
<p class="First">A clinical study has shown that PRISTIQ does not
increase the impairment of mental and motor skills caused by
ethanol. However, as with all CNS-active drugs, patients should be
advised to avoid alcohol consumption while taking PRISTIQ.</p>
</div>
<div class="Section" data-sectioncode="34074-5"><a name="S7.8" id=
"S7.8"></a> <a name="section-7.8" id="section-7.8"></a>
<h2>7.8 Drug-Laboratory Test Interactions</h2>
<p class="First">False-positive urine immunoassay screening tests
for phencyclidine (PCP) and amphetamine have been reported in
patients taking desvenlafaxine. This is due to lack of specificity
of the screening tests. False positive test results may be expected
for several days following discontinuation of desvenlafaxine
therapy. Confirmatory tests, such as gas chromatography/mass
spectrometry, will distinguish desvenlafaxine from PCP and
amphetamine.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">8 USE IN SPECIFIC POPULATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43684-0"><a name="S8" id="S8"></a> <a name="section-8" id=
"section-8"></a>
<div class="Section" data-sectioncode="42228-7"><a name="S8.1" id=
"S8.1"></a> <a name="section-8.1" id="section-8.1"></a>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectioncode="34077-8"><a name=
"section-8.1.1" id="section-8.1.1"></a>
<p class="First"><span class="Bold Underline">Pregnancy Category
C</span></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-8.1.1.1" id="section-8.1.1.1"></a>
<p class="First"><span class="Italics">Risk summary</span></p>
<p>There are no adequate and well-controlled studies of PRISTIQ in
pregnant women. In reproductive developmental studies in rats and
rabbits with desvenlafaxine succinate, evidence of teratogenicity
was not observed at doses up to 30 times a human dose of 100 mg per
day (on a mg/m<span class="Sup">2</span> basis) in rats, and up to
15 times a human dose of 100 mg per day (on a mg/m<span class=
"Sup">2</span> basis) in rabbits. An increase in rat pup deaths was
seen during the first 4 days of lactation when dosing occurred
during gestation and lactation, at doses greater than 10 times a
human dose of 100 mg per day (on a mg/m<span class="Sup">2</span>
basis). PRISTIQ should be used during pregnancy only if the
potential benefits justify the potential risks to the fetus.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-8.1.1.2" id="section-8.1.1.2"></a>
<p class="First"><span class="Italics">Clinical
considerations</span></p>
<p>A prospective longitudinal study of 201 women with history of
major depression who were euthymic at the beginning of pregnancy,
showed women who discontinued antidepressant medication during
pregnancy were more likely to experience a relapse of major
depression than women who continued antidepressant medication.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-8.1.1.3" id="section-8.1.1.3"></a>
<p class="First"><span class="Italics">Human data</span></p>
<p>Neonates exposed to SNRIs (Serotonin and Norepinephrine Reuptake
Inhibitors), or SSRIs (Selective Serotonin Reuptake Inhibitors),
late in the third trimester have developed complications requiring
prolonged hospitalization, respiratory support, and tube feeding.
Such complications can arise immediately upon delivery. Reported
clinical findings have included respiratory distress, cyanosis,
apnea, seizures, temperature instability, feeding difficulty,
vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia,
tremor, jitteriness, irritability, and constant crying. These
features are consistent with either a direct toxic effect of SSRIs
and SNRIs or, possibly, a drug discontinuation syndrome. It should
be noted that, in some cases, the clinical picture is consistent
with serotonin syndrome <span class="Italics">[see <a href=
"#S5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-8.1.1.4" id="section-8.1.1.4"></a>
<p class="First"><span class="Italics">Animal data</span></p>
<p>When desvenlafaxine succinate was administered orally to
pregnant rats and rabbits during the period of organogenesis at
doses up to 300 mg/kg/day and 75 mg/kg/day, respectively, no
teratogenic effects were observed. These doses are 30 times a human
dose of 100 mg per day (on a mg/m<span class="Sup">2</span> basis)
in rats and 15 times a human dose of 100 mg per day (on a
mg/m<span class="Sup">2</span> basis) in rabbits. However, fetal
weights were decreased and skeletal ossification was delayed in
rats in association with maternal toxicity at the highest dose,
with a no-effect dose 10 times a human dose of 100 mg per day (on a
mg/m<span class="Sup">2</span> basis).</p>
<p>When desvenlafaxine succinate was administered orally to
pregnant rats throughout gestation and lactation, there was a
decrease in pup weights and an increase in pup deaths during the
first four days of lactation at the highest dose of 300 mg/kg/day.
The cause of these deaths is not known. The no-effect dose for rat
pup mortality was 10 times a human dose of 100 mg per day (on a
mg/m<span class="Sup">2</span> basis). Post-weaning growth and
reproductive performance of the progeny were not affected by
maternal treatment with desvenlafaxine succinate at a dose 30 times
a human dose of 100 mg per day (on a mg/m<span class="Sup">2</span>
basis).</p>
</div>
</div>
</div>
<div class="Section" data-sectioncode="34080-2"><a name="S8.3" id=
"S8.3"></a> <a name="section-8.2" id="section-8.2"></a>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Desvenlafaxine (O-desmethylvenlafaxine) is
excreted in human milk. Because of the potential for serious
adverse reactions in nursing infants from PRISTIQ, a decision
should be made whether to discontinue nursing or to discontinue the
drug, taking into account the importance of the drug to the
mother.</p>
</div>
<div class="Section" data-sectioncode="34081-0"><a name="S8.4" id=
"S8.4"></a> <a name="section-8.3" id="section-8.3"></a>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients
have not been established <span class="Italics">[see <a href=
"#BOX">Boxed Warning</a> and <a href="#S5.1">Warnings and
Precautions (5.1)</a>]</span>. Anyone considering the use of
PRISTIQ in a child or adolescent must balance the potential risks
with the clinical need.</p>
</div>
<div class="Section" data-sectioncode="34082-8"><a name="S8.5" id=
"S8.5"></a> <a name="section-8.4" id="section-8.4"></a>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 4,158 patients in pre-marketing clinical
studies with PRISTIQ, 6% were 65 years of age or older. No overall
differences in safety or efficacy were observed between these
patients and younger patients; however, in the short-term
placebo-controlled studies, there was a higher incidence of
systolic orthostatic hypotension in patients ≥65 years of age
compared to patients &lt;65 years of age treated with PRISTIQ
<span class="Italics">[see <a href="#S6">Adverse Reactions
(6)</a>]</span>. For elderly patients, possible reduced renal
clearance of PRISTIQ should be considered when determining dose
<span class="Italics">[see <a href="#S2.2">Dosage and
Administration (2.2)</a> and <a href="#S12.3">Clinical Pharmacology
(12.3)</a>]</span>.</p>
<p>SSRIs and SNRIs, including PRISTIQ, have been associated with
cases of clinically significant hyponatremia in elderly patients,
who may be at greater risk for this adverse event <span class=
"Italics">[see <a href="#S5.9">Warnings and Precautions
(5.9)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S8.6" id=
"S8.6"></a> <a name="section-8.5" id="section-8.5"></a>
<h2>8.6 Other Patient Factors</h2>
<p class="First">The effect of intrinsic patient factors on the
pharmacokinetics of PRISTIQ is presented in Figure 3.</p>
<p><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-03.jpg"
alt="Figure 3"></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-8.5.1" id="section-8.5.1"></a>
<p class="First"><span class="Underline">Renal
Impairment:</span></p>
<p>In subjects with renal impairment the clearance of PRISTIQ was
decreased. In subjects with severe renal impairment (24-hr CrCl
&lt;30 mL/min, Cockcroft-Gault) and end-stage renal disease,
elimination half-lives were significantly prolonged, increasing
exposures to PRISTIQ; therefore, dosage adjustment is recommended
in these patients <span class="Italics">[see <a href="#S2.2">Dosage
and Administration (2.2)</a> and <a href="#S12.3">Clinical
Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-8.5.2" id="section-8.5.2"></a>
<p class="First"><span class="Underline">Hepatic
Impairment:</span></p>
<p>The mean terminal half-life (t<span class="Sub">1/2</span>)
changed from approximately 10 hours in healthy subjects and
subjects with mild hepatic impairment to 13 and 14 hours in
moderate and severe hepatic impairment, respectively. The
recommended dose in patients with moderate to severe hepatic
impairment is 50 mg per day. Dose escalation above 100 mg per day
is not recommended <span class="Italics">[see <a href=
"#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">9 DRUG ABUSE AND DEPENDENCE</a>
<div class="Section toggle-content closed" data-sectioncode=
"42227-9"><a name="S9" id="S9"></a> <a name="section-9" id=
"section-9"></a>
<div class="Section" data-sectioncode="34085-1"><a name="S9.1" id=
"S9.1"></a> <a name="section-9.1" id="section-9.1"></a>
<h2>9.1 Controlled Substance</h2>
<p class="First">PRISTIQ is not a controlled substance.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">10 OVERDOSAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34088-5"><a name="S10" id="S10"></a> <a name="section-10" id=
"section-10"></a>
<div class="Section" data-sectioncode="42229-5"><a name="S10.1" id=
"S10.1"></a> <a name="section-10.1" id="section-10.1"></a>
<h2>10.1 Human Experience with Overdosage</h2>
<p class="First">There is limited clinical trial experience with
desvenlafaxine succinate overdosage in humans. However,
desvenlafaxine (PRISTIQ) is the major active metabolite of
venlafaxine. Overdose experience reported with venlafaxine (the
parent drug of PRISTIQ) is presented below; the identical
information can be found in the Overdosage section of the
venlafaxine package insert.</p>
<p>In postmarketing experience, overdose with venlafaxine (the
parent drug of PRISTIQ) has occurred predominantly in combination
with alcohol and/or other drugs. The most commonly reported events
in overdosage include tachycardia, changes in level of
consciousness (ranging from somnolence to coma), mydriasis,
seizures, and vomiting. Electrocardiogram changes (e.g.,
prolongation of QT interval, bundle branch block, QRS
prolongation), sinus and ventricular tachycardia, bradycardia,
hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin
syndrome, and death have been reported.</p>
<p>Published retrospective studies report that venlafaxine
overdosage may be associated with an increased risk of fatal
outcomes compared to that observed with SSRI antidepressant
products, but lower than that for tricyclic antidepressants.
Epidemiological studies have shown that venlafaxine-treated
patients have a higher pre-existing burden of suicide risk factors
than SSRI-treated patients. The extent to which the finding of an
increased risk of fatal outcomes can be attributed to the toxicity
of venlafaxine in overdosage, as opposed to some characteristic(s)
of venlafaxine-treated patients, is not clear.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="S10.2" id=
"S10.2"></a> <a name="section-10.2" id="section-10.2"></a>
<h2>10.2 Management of Overdosage</h2>
<p class="First">No specific antidotes for PRISTIQ are known. In
managing over dosage, consider the possibility of multiple drug
involvement. In case of overdose, call Poison Control Center at
1-800-222-1222 for latest recommendations.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">11 DESCRIPTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34089-3"><a name="S11" id="S11"></a> <a name="section-11" id=
"section-11"></a>
<p class="First">PRISTIQ is an extended-release tablet for oral
administration that contains desvenlafaxine succinate, a
structurally novel SNRI for the treatment of MDD. Desvenlafaxine
(O-desmethylvenlafaxine) is the major active metabolite of the
antidepressant venlafaxine, a medication used to treat major
depressive disorder.</p>
<p>Desvenlafaxine is designated <span class=
"Italics">RS</span>-4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol
and has the empirical formula of C<span class=
"Sub">16</span>H<span class="Sub">25</span>NO<span class=
"Sub">2</span> (free base) and C<span class=
"Sub">16</span>H<span class="Sub">25</span>NO<span class=
"Sub">2</span>∙C<span class="Sub">4</span>H<span class=
"Sub">6</span>O<span class="Sub">4</span>∙H<span class=
"Sub">2</span>O (succinate monohydrate). Desvenlafaxine succinate
monohydrate has a molecular weight of 399.48. The structural
formula is shown below.</p>
<div class="Figure"><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-04.jpg"
alt="Chemical Structure"></div>
<p>Desvenlafaxine succinate is a white to off-white powder that is
soluble in water. The solubility of desvenlafaxine succinate is pH
dependent. Its octanol:aqueous system (at pH 7.0) partition
coefficient is 0.21.</p>
<p>PRISTIQ is formulated as an extended-release tablet for
once-a-day oral administration.</p>
<p>Each tablet contains 38 mg, 76 mg or 152 mg of desvenlafaxine
succinate equivalent to 25 mg, 50 mg or 100 mg of desvenlafaxine,
respectively.</p>
<p>Inactive ingredients for the 25 mg tablet consist of
hypromellose, microcrystalline cellulose, talc, magnesium stearate,
a film coating which consists of polyvinyl alcohol, polyethylene
glycol, talc, titanium dioxide, and iron oxides.</p>
<p>Inactive ingredients for the 50 mg tablet consist of
hypromellose, microcrystalline cellulose, talc, magnesium stearate
and film coating, which consists of polyvinyl alcohol, polyethylene
glycol, talc, titanium dioxide, and iron oxides.</p>
<p>Inactive ingredients for the 100 mg tablet consist of
hypromellose, microcrystalline cellulose, talc, magnesium stearate
and film coating, which consists of polyvinyl alcohol, polyethylene
glycol, talc, titanium dioxide, iron oxide and FD&amp;C yellow
#6.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">12 CLINICAL PHARMACOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"34090-1"><a name="S12" id="S12"></a> <a name="section-12" id=
"section-12"></a>
<div class="Section" data-sectioncode="43679-0"><a name="S12.1" id=
"S12.1"></a> <a name="section-12.1" id="section-12.1"></a>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The exact mechanism of the antidepressant action
of desvenlafaxine is unknown, but is thought to be related to the
potentiation of serotonin and norepinephrine in the central nervous
system, through inhibition of their reuptake. Non-clinical studies
have shown that desvenlafaxine is a potent and selective serotonin
and norepinephrine reuptake inhibitor (SNRI).</p>
</div>
<div class="Section" data-sectioncode="43681-6"><a name="S12.2" id=
"S12.2"></a> <a name="section-12.2" id="section-12.2"></a>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Desvenlafaxine lacked significant affinity for
numerous receptors, including muscarinic-cholinergic, H<span class=
"Sub">1</span>-histaminergic, or α<span class=
"Sub">1</span>-adrenergic receptors <span class="Italics">in
vitro</span>. Desvenlafaxine also lacked monoamine oxidase (MAO)
inhibitory activity.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.2.1" id="section-12.2.1"></a>
<p class="First"><span class="Underline">ECG changes</span></p>
<p>Electrocardiograms were obtained from 1,492 desvenlafaxine
treated patients with major depressive disorder and 984
placebo-treated patients in clinical studies lasting up to 8 weeks.
No clinically relevant differences were observed between
desvenlafaxine treated and placebo-treated patients for QT, QTc,
PR, and QRS intervals. In a thorough QTc study with prospectively
determined criteria, desvenlafaxine did not cause QT prolongation.
No difference was observed between placebo and desvenlafaxine
treatments for the QRS interval.</p>
</div>
</div>
<div class="Section" data-sectioncode="43682-4"><a name="S12.3" id=
"S12.3"></a> <a name="section-12.3" id="section-12.3"></a>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The single-dose pharmacokinetics of desvenlafaxine
are linear and dose-proportional in a dose range of 50 to 600 mg
per day. With once-daily dosing, steady-state plasma concentrations
are achieved within approximately 4 to 5 days. At steady-state,
multiple-dose accumulation of desvenlafaxine is linear and
predictable from the single-dose pharmacokinetic profile.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.1" id="section-12.3.1"></a>
<p class="First"><span class="Bold Underline">Absorption and
distribution</span></p>
<p>The absolute oral bioavailability of PRISTIQ after oral
administration is about 80%.</p>
<p>A food-effect study involving administration of PRISTIQ to
healthy subjects under fasting and fed conditions (high-fat meal,
800 to 1000 calories) indicated that desvenlafaxine C<span class=
"Sub">max</span> was increased about 16% in the fed state, while
the AUCs were similar. This difference is not expected to be
clinically significant; therefore, PRISTIQ can be taken without
regard to meals <span class="Italics">[see <a href="#S2.1">Dosage
and Administration (2.1)</a>]</span>.</p>
<p>The plasma protein binding of desvenlafaxine is low (30%) and is
independent of drug concentration. The desvenlafaxine volume of
distribution at steady-state following intravenous administration
is 3.4 L/kg, indicating distribution into nonvascular
compartments.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.2" id="section-12.3.2"></a>
<p class="First"><span class="Bold Underline">Metabolism and
elimination</span></p>
<p>Desvenlafaxine is primarily metabolized by conjugation (mediated
by UGT isoforms) and, to a minor extent, through oxidative
metabolism. CYP3A4 is the cytochrome P450 isozyme mediating the
oxidative metabolism (N-demethylation) of desvenlafaxine. The
CYP2D6 metabolic pathway is not involved, and after administration
of 100 mg, the pharmacokinetics of desvenlafaxine was similar in
subjects with CYP2D6 poor and extensive metabolizer phenotype.
Approximately 45% of desvenlafaxine is excreted unchanged in urine
at 72 hours after oral administration. Approximately 19% of the
administered dose is excreted as the glucuronide metabolite and
&lt;5% as the oxidative metabolite (N,O-didesmethylvenlafaxine) in
urine.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.3" id="section-12.3.3"></a>
<p class="First"><span class="Bold Underline">Drug interaction
studies</span></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.3.1" id="section-12.3.3.1"></a>
<p class="First"><span class="Italics">Inhibitors of CYP3A4
(ketoconazole)</span></p>
<p>CYP3A4 is a minor pathway for the metabolism of desvenlafaxine.
In a clinical study, ketoconazole (200 mg BID) increased the area
under the concentration vs. time curve (AUC) of desvenlafaxine (400
mg single dose) by about 43% and C<span class="Sub">max</span> by
about 8%. Concomitant use of desvenlafaxine with potent inhibitors
of CYP3A4 may result in higher concentrations of
desvenlafaxine.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.3.2" id="section-12.3.3.2"></a>
<p class="First"><span class="Italics">Inhibitors of other CYP
enzymes</span></p>
<p>Based on in vitro data, drugs that inhibit CYP isozymes 1A1,
1A2, 2A6, 2D6, 2C8, 2C9, 2C19, and 2E1 are not expected to have
significant impact on the pharmacokinetic profile of
desvenlafaxine.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.3.3" id="section-12.3.3.3"></a>
<p class="First"><span class="Italics">Drugs metabolized by CYP2D6
(e.g. desipramine, dextromethorphan, metoprolol,
atomoxetine)</span></p>
<p>In vitro studies showed minimal inhibitory effect of
desvenlafaxine on CYP2D6. Clinical studies have shown that
desvenlafaxine does not have a clinically relevant effect on CYP2D6
metabolism at the dose of 100 mg daily. When desvenlafaxine
succinate was administered at a dose of 100 mg daily in conjunction
with a single 50 mg dose of desipramine, a CYP2D6 substrate, the
C<span class="Sub">max</span> and AUC of desipramine increased
approximately 25% and 17%, respectively. When 400 mg (8 times the
recommended 50 mg dose) was administered, the C<span class=
"Sub">max</span> and AUC of desipramine increased approximately 50%
and 90%, respectively. Concomitant use of desvenlafaxine with a
drug metabolized by CYP2D6 can result in higher concentrations of
that drug <span class="Italics">[see <a href="#S7.5">Drug
Interactions (7.5)</a>].</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.3.4" id="section-12.3.3.4"></a>
<p class="First"><span class="Italics">Drugs metabolized by CYP3A4
(midazolam)</span></p>
<p>In vitro, desvenlafaxine does not inhibit or induce the CYP3A4
isozyme. In a clinical study, desvenlafaxine 400 mg daily (8 times
the recommended 50 mg dose) was co-administered with a single 4 mg
dose of midazolam (a CYP3A4 substrate). The AUC and C<span class=
"Sub">max</span> of midazolam decreased by approximately 31% and
16%, respectively. Concomitant use of desvenlafaxine with a drug
metabolized by CYP3A4 can result in lower exposures to that
drug.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.3.5" id="section-12.3.3.5"></a>
<p class="First"><span class="Italics">Drugs metabolized by CYP1A2,
2A6, 2C8, 2C9 and 2C19</span></p>
<p>In vitro, desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9,
and 2C19 isozymes and would not be expected to affect the
pharmacokinetics of drugs that are metabolized by these CYP
isozymes.</p>
<p>In vitro, desvenlafaxine is not a substrate or an inhibitor for
the P-glycoprotein transporter. The pharmacokinetics of
desvenlafaxine are unlikely to be affected by drugs that inhibit
the P-glycoprotein transporter, and desvenlafaxine is not likely to
affect the pharmacokinetics of drugs that are substrates of the
P-glycoprotein transporter.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.4" id="section-12.3.4"></a>
<p class="First"><span class="Bold Underline">Special
populations</span></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.4.1" id="section-12.3.4.1"></a>
<p class="First"><span class="Bold Italics">Age</span></p>
<p>In a study of healthy subjects administered doses of up to 300
mg, there was an approximate 32% increase in C<span class=
"Sub">max</span> and a 55% increase in AUC in subjects older than
75 years of age (n = 17), compared with subjects 18 to 45 years of
age (n = 16). Subjects 65 to 75 years of age (n = 15) had no change
in C<span class="Sub">max</span>, but an approximately 32% increase
in AUC, compared to subjects 18 to 45 years of age <span class=
"Italics">[see <a href="#S2.2">Dosage and Administration
(2.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.4.2" id="section-12.3.4.2"></a>
<p class="First"><span class="Bold Italics">Gender</span></p>
<p>In a study of healthy subjects administered doses of up to 300
mg, women had an approximately 25% higher C<span class=
"Sub">max</span> and an approximately 10% higher AUC than
age-matched men. No adjustment of dosage on the basis of gender is
needed.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.4.3" id="section-12.3.4.3"></a>
<p class="First"><span class="Bold Italics">Race</span></p>
<p>Pharmacokinetic analysis showed that race (White, n = 466;
Black, n = 97; Hispanic, n = 39; Other, n = 33) had no apparent
effect on the pharmacokinetics of PRISTIQ. No adjustment of dosage
on the basis of race is needed.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.4.4" id="section-12.3.4.4"></a>
<p class="First"><span class="Bold Italics">Hepatic
insufficiency</span></p>
<p>The disposition of desvenlafaxine succinate after administration
of 100 mg was studied in subjects with mild (Child-Pugh A, n = 8),
moderate (Child-Pugh B, n = 8), and severe (Child-Pugh C, n = 8)
hepatic impairment and to healthy subjects (n = 12).</p>
<p>Average AUC was increased by approximately 31% and 35% in
patients with moderate and severe hepatic impairment, respectively,
as compared to healthy subjects. Average AUC values were similar in
subjects with mild hepatic impairment and healthy subjects (&lt; 5%
difference).</p>
<p>Systemic clearance (CL/F) was decreased by approximately 20% and
36% in patients with moderate and severe hepatic impairment,
respectively, as compared to healthy subjects. CL/F values were
comparable in mild hepatic impairment and healthy subjects (&lt; 5%
difference).</p>
<p>The mean t<span class="Sub">1/2</span> changed from
approximately 10 hours in healthy subjects and subjects with mild
hepatic impairment to 13 and 14 hours in moderate and severe
hepatic impairment, respectively. The recommended dose in patients
with hepatic impairment is 50 mg per day. Dose escalation above 100
mg per day is not recommended <span class="Italics">[see <a href=
"#S8.6">Use in Specific Populations (8.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-12.3.4.5" id="section-12.3.4.5"></a>
<p class="First"><span class="Bold Italics">Renal
insufficiency</span></p>
<p>The disposition of desvenlafaxine after administration of 100 mg
was studied in subjects with mild (n = 9), moderate (n = 8), severe
(n = 7) and end-stage renal disease (ESRD) (n = 9) requiring
dialysis and in healthy, age-matched control subjects (n = 8).
Elimination was significantly correlated with creatinine clearance.
Increases in AUCs of about 42% in mild renal impairment (24-hr CrCl
= 50 to 80 mL/min, Cockcroft-Gault [C-G]), about 56% in moderate
renal impairment (24-hr CrCl = 30 to 50 mL/min, C-G), about 108% in
severe renal impairment (24-hr CrCl ≤30 mL/min, C-G), and about
116% in ESRD subjects were observed, compared with healthy,
age-matched control subjects.</p>
<p>The mean terminal half-life (t<span class="Sub">1/2</span>) was
prolonged from 11.1 hours in the control subjects to approximately
13.5, 15.5, 17.6, and 22.8 hours in mild, moderate, severe renal
impairment and ESRD subjects, respectively. Less than 5% of the
drug in the body was cleared during a standard 4-hour hemodialysis
procedure.</p>
<p>The maximum recommended dose in patients with moderate renal
impairment is 50 mg per day. Dosage adjustment of 50 mg every other
day is recommended in patients with severe renal impairment or
ESRD. [<span class="Italics">see <a href="#S2.2">Dosage and
Administration (2.2)</a> and <a href="#S8.6">Use in Specific
Populations (8.6)</a></span>].</p>
</div>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">13 NONCLINICAL TOXICOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"43680-8"><a name="S13" id="S13"></a> <a name="section-13" id=
"section-13"></a>
<div class="Section" data-sectioncode="34083-6"><a name="S13.1" id=
"S13.1"></a> <a name="section-13.1" id="section-13.1"></a>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-13.1.1" id="section-13.1.1"></a>
<p class="First"><span class="Underline">Carcinogenesis</span></p>
<p>Desvenlafaxine succinate administered by oral gavage to mice and
rats for 2 years did not increase the incidence of tumors in either
study.</p>
<p>Mice received desvenlafaxine succinate at dosages up to 500/300
mg/kg/day (dosage lowered after 45 weeks of dosing). The 300
mg/kg/day dose is 15 times a human dose of 100 mg per day on a
mg/m<span class="Sup">2</span> basis.</p>
<p>Rats received desvenlafaxine succinate at dosages up to 300
mg/kg/day (males) or 500 mg/kg/day (females). The highest dose is
29 (males) or 48 (females) times a human dose of 100 mg per day on
a mg/m<span class="Sup">2</span> basis.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-13.1.2" id="section-13.1.2"></a>
<p class="First"><span class="Underline">Mutagenesis</span></p>
<p>Desvenlafaxine was not mutagenic in the <span class="Italics">in
vitro</span> bacterial mutation assay (Ames test) and was not
clastogenic in an <span class="Italics">in vitro</span> chromosome
aberration assay in cultured CHO cells, an <span class="Italics">in
vivo</span> mouse micronucleus assay, or an <span class=
"Italics">in vivo</span> chromosome aberration assay in rats.
Additionally, desvenlafaxine was not genotoxic in the <span class=
"Italics">in vitro</span> CHO mammalian cell forward mutation assay
and was negative in the <span class="Italics">in vitro</span>
BALB/c-3T3 mouse embryo cell transformation assay.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-13.1.3" id="section-13.1.3"></a>
<p class="First"><span class="Underline">Impairment of
fertility</span></p>
<p>When desvenlafaxine succinate was administered orally to male
and female rats, fertility was reduced at the high dose of 300
mg/kg/day, which is 30 times a human dose of 100 mg per day (on a
mg/m<span class="Sup">2</span> basis). There was no effect on
fertility at 100 mg/kg/day, approximately 10 times a human dose of
100 mg per day (on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">14 CLINICAL STUDIES</a>
<div class="Section toggle-content closed" data-sectioncode=
"34092-7"><a name="S14" id="S14"></a> <a name="section-14" id=
"section-14"></a>
<p class="First">The efficacy of PRISTIQ as a treatment for
depression was established in four 8-week, randomized,
double-blind, placebo-controlled, fixed-dose studies (at doses of
50 mg per day to 400 mg per day) in adult outpatients who met the
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
criteria for major depressive disorder. In the first study,
patients received 100 mg (n = 114), 200 mg (n = 116), or 400 mg (n
= 113) of PRISTIQ once daily, or placebo (n = 118). In a second
study, patients received either 200 mg (n = 121) or 400 mg (n =
124) of PRISTIQ once daily, or placebo (n = 124). In two additional
studies, patients received 50 mg (n = 150 and n = 164) or 100 mg (n
= 147 and n = 158) of PRISTIQ once daily, or placebo (n = 150 and n
= 161).</p>
<p>PRISTIQ showed superiority over placebo as measured by
improvement in the 17-item Hamilton Rating Scale for Depression
(HAM-D<span class="Sub">17</span>) total score in four studies and
overall improvement, as measured by the Clinical Global Impressions
Scale - Improvement (CGI-I), in three of the four studies. In
studies directly comparing 50 mg per day and 100 mg per day there
was no suggestion of a greater effect with the higher dose and
adverse reactions and discontinuations were more frequent at higher
doses [<span class="Italics">see <a href="#S2.1">Dosage and
Administration (2.1)</a></span>].</p>
<a name="table8" id="table8"></a>
<div class="scrollingtable">
<table width="80%">
<caption><span>Table 8: Primary Efficacy (HAM-D<span class=
"Sub">17</span>) Results for Short-term Studies</span></caption>
<colgroup>
<col align="center" valign="top" width="7%">
<col align="left" valign="top" width="18%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%"></colgroup>
<thead>
<tr class="First">
<th align="center"></th>
<th align="left"></th>
<th align="center"></th>
<th class="Botrule" align="center" colspan="4">PRISTIQ</th>
</tr>
<tr class="Last">
<th align="center">Study No.</th>
<th align="left">Primary Endpoint: HAM-D<span class=
"Sub">17</span></th>
<th align="center">Placebo</th>
<th align="center">50 mg/day</th>
<th align="center">100 mg/day</th>
<th align="center">200 mg/day</th>
<th align="center">400 mg/day</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="7">
<dl class="Footnote">
<dt><a href="#footnote-reference-1" name="footnote-1" id=
"footnote-1">*</a></dt>
<dd>Standard deviation;</dd>
<dt><a href="#footnote-reference-2" name="footnote-2" id=
"footnote-2">†</a></dt>
<dd>Difference between least squares means at final evaluation,
calculated as drug response minus placebo response; unadjusted 95%
confidence intervals</dd>
<dt><a href="#footnote-reference-3" name="footnote-3" id=
"footnote-3">‡</a></dt>
<dd>Adjusted p-value &lt; 0.05;</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody>
<tr class="First">
<td align="center" rowspan="2">1</td>
<td align="left">Baseline Score (SD<a class="Sup" href=
"#footnote-1" name="footnote-reference-1" id=
"footnote-reference-1">*</a>)</td>
<td align="center">23.1 (2.5)</td>
<td align="center"></td>
<td align="center">23.2 (2.5)</td>
<td align="center">22.9 (2.4)</td>
<td align="center">23.0 (2.2)</td>
</tr>
<tr>
<td align="left">Difference from Placebo (95% CI <a class="Sup"
href="#footnote-2" name="footnote-reference-2" id=
"footnote-reference-2">†</a>)</td>
<td align="left"></td>
<td align="center"></td>
<td align="center">-2.9<a class="Sup" href="#footnote-3" name=
"footnote-reference-3" id="footnote-reference-3">‡</a><br>
(-5.1, -0.8)</td>
<td align="center">-2.0<br>
<br></td>
<td align="center">-3.1<a class="Sup" href="#footnote-3">‡</a><br>
(-5.2, -0.9)</td>
</tr>
<tr>
<td align="center" rowspan="2">2<br>
<br>
<br>
<br></td>
<td align="left">Baseline Score (SD<a class="Sup" href=
"#footnote-1">*</a>)</td>
<td align="center">25.3 (3.3)</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">24.8 (2.9)</td>
<td align="center">25.2 (3.2)</td>
</tr>
<tr>
<td align="left">Difference from Placebo (95% CI <a class="Sup"
href="#footnote-2">†</a>)</td>
<td align="left"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">-3.3<a class="Sup" href="#footnote-3">‡</a><br>
(-5.3, -1.2)</td>
<td align="center">-2.8<a class="Sup" href="#footnote-3">‡</a><br>
(-4.8, -0.7)</td>
</tr>
<tr>
<td align="center" rowspan="2">3<br>
<br>
<br>
<br></td>
<td align="left">Baseline Score (SD<a class="Sup" href=
"#footnote-1">*</a>)</td>
<td align="center">23.0 (2.6)</td>
<td align="center">23.4 (2.6)</td>
<td align="center">23.4 (2.6)</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">Difference from Placebo (95% CI <a class="Sup"
href="#footnote-2">†</a>)</td>
<td align="left"></td>
<td align="center">-1.9<a class="Sup" href="#footnote-3">‡</a><br>
(-3.5, -0.3)</td>
<td align="center">-1.5<br></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Botrule" align="center" rowspan="2">4<br>
<br>
<br>
<br></td>
<td align="left">Baseline Score (SD<a class="Sup" href=
"#footnote-1">*</a>)</td>
<td align="center">24.3 (2.6)</td>
<td align="center">24.3 (2.4)</td>
<td align="center">24.4 (2.7)</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule Last">
<td align="left">Difference from Placebo (95% CI <a class="Sup"
href="#footnote-2">†</a>)</td>
<td align="left"></td>
<td align="center">-2.5<a class="Sup" href="#footnote-3">‡</a><br>
(-4.1, -0.9)</td>
<td align="center">-3.0<a class="Sup" href="#footnote-3">‡</a><br>
(-4.7, -1.4)</td>
<td align="center"></td>
<td align="center"></td>
</tr>
</tbody>
</table>
</div>
<p>Analyses of the relationships between treatment outcome and age
and treatment outcome and gender did not suggest any differential
responsiveness on the basis of these patient characteristics. There
was insufficient information to determine the effect of race on
outcome in these studies.</p>
<p>In a longer-term trial (Study 5), adult outpatients meeting
DSM-IV criteria for major depressive disorder, who responded to 8
weeks of open-label acute treatment with 50 mg per day
desvenlafaxine and subsequently remained stable for 12 weeks on
desvenlafaxine, were assigned randomly in a double-blind manner to
remain on active treatment or switch to placebo for up to 26 weeks
of observation for relapse. Response during the open-label phase
was defined as a HAM-D<span class="Sub">17</span> total score of ≤
11 and CGI-I ≤ 2 at the day 56 evaluation; stability was defined as
HAM-D<span class="Sub">17</span> total score of ≤ 11 and CGI-I ≤ 2
at week 20 and not having a HAM-D<span class="Sub">17</span> total
score of ≥ 16 or a CGI-I score ≥ 4 at any office visit. Relapse
during the double-blind phase was defined as follows: (1) a
HAM-D<span class="Sub">17</span> total score of ≥ 16 at any office
visit, (2) discontinuation for unsatisfactory efficacy response,
(3) hospitalized for depression, (4) suicide attempt, or (5)
suicide. Patients receiving continued desvenlafaxine treatment
experienced statistically significantly longer time to relapse
compared with placebo. At 26 weeks, the Kaplan-Meier estimated
proportion of relapse was 14% with desvenlafaxine treatment versus
30% with placebo.</p>
<div class="scrollingtable">
<table class="Noautorules" width="75%">
<colgroup>
<col align="center" valign="top" width="100%"></colgroup>
<tbody class="Headless">
<tr>
<td align="center"><span class="Bold">Figure 4. Estimated
Proportion of Relapses vs. Number of Days since Randomization
(Study 5)</span></td>
</tr>
<tr>
<td align="center">
<p class="First"><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-05.jpg"
alt="Figure 4"></p>
</td>
</tr>
</tbody>
</table>
</div>
<p>In another longer-term trial (Study 6), adult outpatients
meeting DSM-IV criteria for major depressive disorder and who
responded to 12 weeks of acute treatment with desvenlafaxine were
assigned randomly to the same dose (200 or 400 mg per day) they had
received during acute treatment or to placebo for up to 26 weeks of
observation for relapse. Response during the open-label phase was
defined as a HAM-D<span class="Sub">17</span> total score of ≤ 11
at the day 84 evaluation. Relapse during the double-blind phase was
defined as follows: (1) a HAM-D<span class="Sub">17</span> total
score of ≥ 16 at any office visit, (2) a CGI-I score of ≥ 6 (versus
day 84) at any office visit, or (3) discontinuation from the trial
due to unsatisfactory response. Patients receiving continued
desvenlafaxine treatment experienced statistically significantly
longer time to relapse over the subsequent 26 weeks compared with
those receiving placebo. At 26 weeks, the Kaplan-Meier estimated
proportion of relapse was 29% with desvenlafaxine treatment versus
49% with placebo.</p>
<div class="scrollingtable">
<table class="Noautorules" width="75%">
<colgroup>
<col align="center" valign="top" width="100%"></colgroup>
<tbody class="Headless">
<tr>
<td align="center"><span class="Bold">Figure 5. Estimated
Proportion of Relapses vs. Number of Days since Randomization
(Study 6)</span></td>
</tr>
<tr>
<td align="center">
<p class="First"><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-06.jpg"
alt="Figure 5"></p>
</td>
</tr>
</tbody>
</table>
</div>
<p>In a postmarketing study, the efficacy of PRISTIQ at a dose
lower than 50 mg per day was evaluated in an 8-week, multicenter,
randomized, double-blind, placebo-controlled, fixed-dose study in
adult outpatients with Major Depressive Disorder. The treatment
arms were 25 mg (n=232), 50 mg (n=236), and placebo (n=231). The 50
mg dose was superior to placebo, as measured by the mean change
from baseline on the HAMD-17. The 25 mg dose was not superior to
placebo.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a>
<div class="Section toggle-content closed" data-sectioncode=
"34069-5"><a name="S16" id="S16"></a> <a name="section-15" id=
"section-15"></a>
<p class="First">PRISTIQ (desvenlafaxine) Extended-Release Tablets
are available as follows:</p>
<p><span class="Bold">25 mg, tan, square pyramid tablet debossed
with "W" (over) "25" on the flat side</span></p>
<dl>
<dd>NDC 0008-1210-30, bottle of 30 tablets in unit-of-use
package</dd>
</dl>
<p><span class="Bold">50 mg, light pink, square pyramid tablet
debossed with "W" (over) "50" on the flat side</span></p>
<dl>
<dd>NDC 0008-1211-14, bottle of 14 tablets in unit-of-use
package</dd>
<dd>NDC 0008-1211-30, bottle of 30 tablets in unit-of-use
package</dd>
<dd>NDC 0008-1211-01, bottle of 90 tablets in unit-of-use
package</dd>
<dd>NDC 0008-1211-50, 10 blisters of 10 (HUD)</dd>
</dl>
<p><span class="Bold">100 mg, reddish-orange, square pyramid tablet
debossed with "W" (over) "100" on the flat side</span></p>
<dl>
<dd>NDC 0008-1222-14, bottle of 14 tablets in unit-of-use
package</dd>
<dd>NDC 0008-1222-30, bottle of 30 tablets in unit-of-use
package</dd>
<dd>NDC 0008-1222-01, bottle of 90 tablets in unit-of-use
package</dd>
<dd>NDC 0008-1222-50, 10 blisters of 10 (HUD)</dd>
</dl>
<div class="Section" data-sectioncode="44425-7"><a name=
"section-15.1" id="section-15.1"></a>
<p class="First">Store at 20° to 25°C (68° to 77°F); excursions
permitted to 15° to 30°C (59° to 86°F) <span class="Italics">[see
USP Controlled Room Temperature]</span>.</p>
<p>Each tablet contains 38 mg, 76 mg or 152 mg of desvenlafaxine
succinate equivalent to 25 mg, 50 mg or 100 mg of desvenlafaxine,
respectively.</p>
<p>The unit-of-use package is intended to be dispensed as a
unit.</p>
<p>The appearance of these tablets is a trademark of Wyeth
Pharmaceuticals.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">17 PATIENT COUNSELING INFORMATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34076-0"><a name="S17" id="S17"></a> <a name="section-16" id=
"section-16"></a>
<p class="First">See FDA-approved patient labeling (<a href=
"#MG">Medication Guide</a>).</p>
<p>Advise patients, their families, and their caregivers about the
benefits and risks associated with treatment with PRISTIQ and
counsel them in its appropriate use.</p>
<p>Advise patients, their families, and their caregivers to read
the Medication Guide and assist them in understanding its contents.
The complete text of the Medication Guide is reprinted at the end
of this document.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.1" id="section-16.1"></a>
<p class="First"><span class="Bold Underline">Suicide
Risk</span></p>
<p>Advise patients, their families and caregivers to look for the
emergence of suicidality, especially early during treatment and
when the dose is adjusted up or down <span class="Italics">[see
<a href="#BOX">Boxed Warning</a> and <a href="#S5.1">Warnings and
Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.2" id="section-16.2"></a>
<p class="First"><span class="Bold Underline">Concomitant
Medication</span></p>
<p>Advise patients taking PRISTIQ not to use concomitantly other
products containing desvenlafaxine or venlafaxine. Healthcare
professionals should instruct patients not to take PRISTIQ with an
MAOI or within 14 days of stopping an MAOI and to allow 7 days
after stopping PRISTIQ before starting an MAOI <span class=
"Italics">[see <a href="#S4">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.3" id="section-16.3"></a>
<p class="First"><span class="Bold Underline">Serotonin
Syndrome</span></p>
<p>Caution patients about the risk of serotonin syndrome,
particularly with the concomitant use of PRISTIQ with other
serotonergic agents (including triptans, tricyclic antidepressants,
fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's
Wort supplements) [<span class="Italics">see <a href=
"#S5.2">Warnings and Precautions (5.2)</a></span>].</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.4" id="section-16.4"></a>
<p class="First"><span class="Bold Underline">Elevated Blood
Pressure</span></p>
<p>Advise patients that they should have regular monitoring of
blood pressure when taking PRISTIQ <span class="Italics">[see
<a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.5" id="section-16.5"></a>
<p class="First"><span class="Bold Underline">Abnormal
Bleeding</span></p>
<p>Patients should be cautioned about the concomitant use of
PRISTIQ and NSAIDs, aspirin, warfarin, or other drugs that affect
coagulation since combined use of psychotropic drugs that interfere
with serotonin reuptake and these agents has been associated with
an increased risk of bleeding <span class="Italics">[see <a href=
"#S5.4">Warnings and Precautions (5.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.6" id="section-16.6"></a>
<p class="First"><span class="Bold Underline">Angle Closure
Glaucoma</span></p>
<p>Patients should be advised that taking Pristiq can cause mild
pupillary dilation, which in susceptible individuals, can lead to
an episode of angle closure glaucoma. Pre-existing glaucoma is
almost always open-angle glaucoma because angle closure glaucoma,
when diagnosed, can be treated definitively with iridectomy.
Open-angle glaucoma is not a risk factor for angle closure
glaucoma. Patients may wish to be examined to determine whether
they are susceptible to angle closure, and have a prophylactic
procedure (e.g., iridectomy), if they are susceptible. [see
<a href="#S5.5">Warnings and Precautions (5.5)</a>]</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.7" id="section-16.7"></a>
<p class="First"><span class="Bold Underline">Activation of
Mania/Hypomania</span></p>
<p>Advise patients, their families and caregivers to observe for
signs of activation of mania/hypomania <span class="Italics">[see
<a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.8" id="section-16.8"></a>
<p class="First"><span class=
"Bold Underline">Discontinuation</span></p>
<p>Advise patients not to stop taking PRISTIQ without talking first
with their healthcare professional. Patients should be aware that
discontinuation effects may occur when stopping PRISTIQ, and a dose
of 25 mg per day is available for discontinuing therapy
<span class="Italics">[see <a href="#S5.7">Warnings and Precautions
(5.7)</a> and <a href="#S6.1">Adverse Reactions
(6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.9" id="section-16.9"></a>
<p class="First"><span class="Bold Underline">Switching Patients
From Other Antidepressants to PRISTIQ</span></p>
<p>Discontinuation symptoms have been reported when switching
patients from other antidepressants, including venlafaxine, to
PRISTIQ. Tapering of the initial antidepressant may be necessary to
minimize discontinuation symptoms.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.10" id="section-16.10"></a>
<p class="First"><span class="Bold Underline">Interference with
Cognitive and Motor Performance</span></p>
<p>Caution patients about operating hazardous machinery, including
automobiles, until they are reasonably certain that PRISTIQ therapy
does not adversely affect their ability to engage in such
activities.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.11" id="section-16.11"></a>
<p class="First"><span class="Bold Underline">Alcohol</span></p>
<p>Advise patients to avoid alcohol while taking PRISTIQ
<span class="Italics">[see <a href="#S7.7">Drug Interactions
(7.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.12" id="section-16.12"></a>
<p class="First"><span class="Bold Underline">Allergic
Reactions</span></p>
<p>Advise patients to notify their physician if they develop
allergic phenomena such as rash, hives, swelling, or difficulty
breathing.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.13" id="section-16.13"></a>
<p class="First"><span class="Bold Underline">Pregnancy</span></p>
<p>Advise patients to notify their physician if they become
pregnant or intend to become pregnant during therapy <span class=
"Italics">[see <a href="#S8.1">Use in Specific Populations
(8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.14" id="section-16.14"></a>
<p class="First"><span class="Bold Underline">Nursing</span></p>
<p>Advise patients to notify their physician if they are
breastfeeding an infant <span class="Italics">[see <a href=
"#S8.3">Use in Specific Populations (8.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"section-16.15" id="section-16.15"></a>
<p class="First"><span class="Bold Underline">Residual Inert Matrix
Tablet</span></p>
<p>Patients receiving PRISTIQ may notice an inert matrix tablet
passing in the stool or via colostomy. Patients should be informed
that the active medication has already been absorbed by the time
the patient sees the inert matrix tablet.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">SPL UNCLASSIFIED SECTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"42229-5"><a name="section-17" id="section-17"></a>
<p class="First"><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-07.jpg"
alt="Logo"></p>
<p>LAB-0452-14</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">MEDICATION GUIDE</a>
<div class="Section toggle-content closed" data-sectioncode=
"42231-1"><a name="MG" id="MG"></a> <a name="section-18" id=
"section-18"></a>
<p class="First">PRISTIQ<span class="Sup">®</span>
(pris-<span class="Bold">TEEK</span>)<br>
(desvenlafaxine)<br>
Extended-Release Tablets</p>
<p>Read this Medication Guide before you start taking PRISTIQ and
each time you get a refill. There may be new information. This
information does not take the place of talking to your healthcare
provider about your medical condition or treatment.</p>
<p><a name="anti" id="anti"></a><span class="Bold">Antidepressant
Medicines, Depression and Other Serious Mental Illnesses, and
Suicidal Thoughts or Actions</span></p>
<p><span class="Bold">Talk to your healthcare provider
about:</span></p>
<ul>
<li>all risks and benefits of treatment with antidepressant
medicines</li>
<li>all treatment choices for depression or other serious mental
illness</li>
</ul>
<p><span class="Bold">What is the most important information I
should know about antidepressant medicines, depression and other
serious mental illnesses, and suicidal thoughts or
actions?</span></p>
<ol class="Arabic">
<li><span class="Bold">Antidepressant medicines may increase
suicidal thoughts or actions in some children, teenagers, and young
adults within the first few months of treatment.</span></li>
<li><span class="Bold">Depression and other serious mental
illnesses are the most important causes of suicidal thoughts and
actions. Some people may have a particularly high risk of having
suicidal thoughts or actions.</span> These include people who have
(or have a family history of) bipolar illness (also called
manic-depressive illness) or suicidal thoughts or actions.</li>
<li><span class="Bold">How can I watch for and try to prevent
suicidal thoughts and actions?</span>
<ul class="Disc">
<li>Pay close attention to any changes, especially sudden changes,
in mood, behaviors, thoughts, or feelings. This is very important
when an antidepressant medicine is started or when the dose is
changed.</li>
<li>Call the healthcare provider right away to report new or sudden
changes in mood, behavior, thoughts, or feelings.</li>
<li>Keep all follow-up visits with the healthcare provider as
scheduled. Call the healthcare provider between visits as needed,
especially if you have concerns about symptoms.</li>
</ul>
</li>
</ol>
<p><span class="Bold">Call a healthcare provider right away if you
have any of the following symptoms, especially if they are new,
worse, or worry you:</span></p>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%"></colgroup>
<tbody class="Headless">
<tr class="First Last">
<td align="left">
<ul class="Disc">
<li>thoughts about suicide or dying</li>
<li>attempts to commit suicide</li>
<li>new or worse depression</li>
<li>new or worse anxiety</li>
<li>feeling very agitated or restless</li>
<li>panic attacks</li>
</ul>
</td>
<td align="left">
<ul class="Disc">
<li>trouble sleeping (insomnia)</li>
<li>new or worse irritability</li>
<li>acting aggressive, being angry, or violent</li>
<li>acting on dangerous impulses</li>
<li>an extreme increase in activity and talking (mania)</li>
<li>other unusual changes in behavior or mood</li>
</ul>
</td>
</tr>
</tbody>
</table>
</div>
<p><span class="Bold">What else do I need to know about
antidepressant medicines?</span></p>
<ul>
<li>Never stop an antidepressant medicine without first talking to
a healthcare provider. Stopping an antidepressant medicine suddenly
can cause other symptoms.</li>
<li><span class="Bold">Antidepressants are medicines used to treat
depression and other illnesses.</span> It is important to discuss
all the risks of treating depression and also the risks of not
treating it. Patients should discuss all treatment choices with the
healthcare provider, not just the use of antidepressants.</li>
<li><span class="Bold">Antidepressant medicines have other side
effects.</span> Talk to the healthcare provider about the side
effects of this medicine.</li>
<li><span class="Bold">Antidepressant medicines can interact with
other medicines.</span> Know all of the medicines that you take.
Keep a list of all medicines to show the healthcare provider. Do
not start new medicines without first checking with your healthcare
provider.</li>
<li><span class="Bold">Not all antidepressant medicines prescribed
for children are FDA approved for use in children.</span> Talk to
your child's healthcare provider for more information.</li>
</ul>
<p><span class="Bold">Important Information about PRISTIQ
Extended-Release Tablets</span></p>
<p>Read the patient information that comes with PRISTIQ before you
take PRISTIQ and each time you refill your prescription. There may
be new information. If you have questions, ask your healthcare
provider. This information does not take the place of talking with
your healthcare provider about your medical condition or
treatment.</p>
<p><span class="Bold">What is PRISTIQ?</span></p>
<ul>
<li>PRISTIQ is a prescription medicine used to treat depression.
PRISTIQ belongs to a class of medicines known as SNRIs (or
serotonin-norepinephrine reuptake inhibitors).</li>
</ul>
<p><span class="Bold">Who should not take PRISTIQ?</span></p>
<p><span class="Bold">Do not take PRISTIQ if you:</span></p>
<ul>
<li>are allergic to desvenlafaxine, venlafaxine or any of the
ingredients in PRISTIQ. See the end of this Medication Guide for a
complete list of ingredients in PRISTIQ.</li>
<li>take a monoamine oxidase inhibitor (MAOI). Ask your healthcare
provider or pharmacist if you are not sure if you take an MAOI,
including the antibiotic linezolid and the intravenous medicine
methylene blue.</li>
<li>have taken an MAOI within 7 days of stopping PRISTIQ unless
directed by your healthcare provider.</li>
<li>have started PRISTIQ and if you stopped taking an MAOI in the
last 14 days unless directed by your healthcare provider.</li>
</ul>
<p><a name="should" id="should"></a><span class="Bold">What should
I tell my healthcare provider before taking PRISTIQ?</span></p>
<p>Tell your healthcare provider about all your medical conditions,
including if you:</p>
<ul>
<li>have high blood pressure</li>
<li>have heart problems</li>
<li>have high cholesterol or high triglycerides</li>
<li>have a history of a stroke</li>
<li>have or had depression, suicidal thoughts or behavior</li>
<li>have kidney problems</li>
<li>have liver problems</li>
<li>have or had bleeding problems</li>
<li>have or had seizures or convulsions</li>
<li>have mania or bipolar disorder</li>
<li>have low sodium levels in your blood</li>
<li>are pregnant or plan to become pregnant. It is not known if
PRISTIQ will harm your unborn baby.</li>
<li>are breastfeeding. PRISTIQ can pass into your breast milk and
may harm your baby. Talk with your healthcare provider about the
best way to feed your baby if you take PRISTIQ.</li>
</ul>
<p><span class="Bold">Serotonin syndrome</span></p>
<p>Rare, but potentially life-threatening conditions called
serotonin syndrome can happen when medicines such as PRISTIQ are
taken with certain other medicines. Serotonin syndrome can cause
serious changes in how your brain, muscles, heart and blood
vessels, and digestive system work. <span class="Bold">Especially
tell your healthcare provider if you take the following:</span></p>
<ul>
<li>medicines to treat migraine headaches known as triptans</li>
<li>medicines used to treat mood, anxiety, psychotic, or thought
disorders, including tricyclics, lithium, selective serotonin
reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake
inhibitors (SNRIs), or other dopamine antagonists, such as
metoclopramide</li>
<li>silbutramine</li>
<li>tramadol</li>
<li>St. John's Wort</li>
<li>MAOIs (including linezolid, an antibiotic and intravenous
methylene blue)</li>
<li>tryptophan supplements</li>
</ul>
<p>Ask your healthcare provider if you are not sure if you are
taking any of these medicines.</p>
<p>Before you take PRISTIQ with any of these medicines, talk to
your healthcare provider about serotonin syndrome. See "<a href=
"#possible">What are the possible side effects of PRISTIQ?</a>"</p>
<p><span class="Bold">Do not take PRISTIQ with other medicines
containing venlafaxine or desvenlafaxine.</span></p>
<p><span class="Bold">How should I take PRISTIQ?</span></p>
<ul>
<li>Take PRISTIQ exactly as your healthcare provider has told
you.</li>
<li>Take PRISTIQ at about the same time each day.</li>
<li>PRISTIQ may be taken either with or without food.</li>
<li>Swallow PRISTIQ tablets whole, with fluid. Do not crush, cut,
chew, or dissolve PRISTIQ tablets because the tablets are
time-released.</li>
<li>When you take PRISTIQ, you may see something in your stool that
looks like a tablet. This is the empty shell from the tablet after
the medicine has been absorbed by your body.</li>
<li>It is common for antidepressant medicines such as PRISTIQ to
take several weeks before you start to feel better. Do not stop
taking PRISTIQ if you do not feel results right away.</li>
<li>Do not stop taking or change the dose of PRISTIQ without
talking with your healthcare provider, even if you feel
better.</li>
<li>Talk with your healthcare provider about how long you should
use PRISTIQ. Take PRISTIQ for as long as your healthcare provider
tells you to.</li>
<li>If you miss a dose of PRISTIQ, take it as soon as you remember.
If it is almost time for your next dose, skip the missed dose. Do
not try to "make up" for the missed dose by taking two doses at the
same time.</li>
<li>Do not take more PRISTIQ than prescribed by your healthcare
provider. If you take more PRISTIQ than the amount prescribed,
contact your healthcare provider right away.</li>
<li>If you take too much PRISTIQ, call the Poison Control Center at
1-800-222-1222 or go to the nearest hospital emergency room right
away.</li>
</ul>
<p><span class="Bold">Switching from other
antidepressants</span></p>
<p>Side effects from discontinuing antidepressant medication have
occurred when patients switched from other antidepressants,
including venlafaxine, to PRISTIQ. Your doctor may gradually reduce
the dose of your initial antidepressant medication to help to
reduce these side effects.</p>
<p><span class="Bold">What should I avoid while taking
PRISTIQ?</span></p>
<ul>
<li>Do not drive a car or operate machinery until you know how
PRISTIQ affects you.</li>
<li>Avoid drinking alcohol while taking PRISTIQ.</li>
</ul>
<p><a name="possible" id="possible"></a><span class="Bold">What are
the possible side effects of PRISTIQ?</span></p>
<p><span class="Bold">PRISTIQ can cause serious side effects,
including:</span></p>
<ul>
<li><span class="Bold">See the beginning of this <a href=
"#anti">Medication Guide -Antidepressant Medicines, Depression and
other Serious Mental Illnesses, and Suicidal Thoughts or
Actions</a>.</span></li>
<li><span class="Bold">Serotonin syndrome. See "<a href=
"#should">What should I tell my healthcare provider before taking
PRISTIQ?</a>"</span><br>
Get medical help right away if you think that you have these
syndromes. Signs and symptoms of these syndromes may include one or
more of the following:</li>
</ul>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%"></colgroup>
<tbody class="Headless">
<tr class="First Last">
<td align="left">
<ul class="Disc">
<li>restlessness</li>
<li>hallucinations (seeing and hearing things that are not
real)</li>
<li>loss of coordination</li>
<li>fast heart beat</li>
<li>increased body temperature</li>
<li>muscle stiffness</li>
</ul>
</td>
<td align="left">
<ul class="Disc">
<li>increase in blood pressure</li>
<li>diarrhea</li>
<li>coma</li>
<li>nausea</li>
<li>vomiting</li>
<li>confusion</li>
</ul>
</td>
</tr>
</tbody>
</table>
</div>
<p><span class="Bold">PRISTIQ may also cause other serious side
effects, including:</span></p>
<ul>
<li><span class="Bold">New or worsened high blood pressure
(hypertension).</span> Your healthcare provider should monitor your
blood pressure before and while you are taking PRISTIQ. If you have
high blood pressure, it should be controlled before you start
taking PRISTIQ.</li>
<li><span class="Bold">Abnormal bleeding or bruising.</span>
PRISTIQ and other SNRIs/SSRIs may cause you to have an increased
chance of bleeding. Taking aspirin, NSAIDs (non-steroidal
anti-inflammatory drugs), or blood thinners may add to this risk.
Tell your healthcare provider right away about any unusual bleeding
or bruising.</li>
<li><span class="Bold">Visual problems</span>
<ul class="Disc">
<li>eye pain</li>
<li>changes in vision</li>
<li>swelling or redness in or around the eye</li>
</ul>
Only some people are at risk for these problems. You may want to
undergo an eye examination to see if you are at risk and receive
preventative treatment if you are.<br>
<span class="Bold">Symptoms when stopping PRISTIQ (discontinuation
symptoms).</span> Side effects may occur when stopping PRISTIQ
(discontinuation symptoms), especially when therapy is stopped
suddenly. Your healthcare provider may want to decrease your dose
slowly to help avoid side effects. Some of these side effects may
include:</li>
</ul>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%"></colgroup>
<tbody class="Headless">
<tr class="First Last">
<td align="left">
<ul class="Disc">
<li>dizziness</li>
<li>nausea</li>
<li>headache</li>
<li>irritability</li>
<li>sleeping problems (insomnia)</li>
</ul>
</td>
<td align="left">
<ul class="Disc">
<li>anxiety</li>
<li>abnormal dreams</li>
<li>tiredness</li>
<li>sweating</li>
<li>diarrhea</li>
</ul>
</td>
</tr>
</tbody>
</table>
</div>
<ul>
<li><span class="Bold">Seizures (convulsions)</span></li>
<li><span class="Bold">Low sodium levels in your blood.</span>
Symptoms of this may include: headache, difficulty concentrating,
memory changes, confusion, weakness and unsteadiness on your feet.
In severe or more sudden cases, symptoms can include:
hallucinations (seeing or hearing things that are not real),
fainting, seizures and coma. If not treated, severe low sodium
levels could be fatal.</li>
<li><span class="Bold">Lung problems.</span> Some people who have
taken the medicine venlafaxine which is the same kind of medicine
as the medicine in PRISTIQ have had lung problems. Symptoms of lung
problems include difficulty breathing, cough, or chest discomfort.
Tell your healthcare provider right away if you have any of these
symptoms.</li>
</ul>
<p>Common side effects with PRISTIQ include:</p>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%"></colgroup>
<tbody class="Headless">
<tr class="First Last">
<td align="left">
<ul class="Disc">
<li>nausea</li>
<li>dizziness</li>
<li>insomnia</li>
<li>sweating</li>
<li>constipation</li>
</ul>
</td>
<td align="left">
<ul class="Disc">
<li>sleepiness</li>
<li>loss of appetite</li>
<li>anxiety</li>
<li>decreased sex drive</li>
<li>delayed orgasm and ejaculation</li>
</ul>
</td>
</tr>
</tbody>
</table>
</div>
<p>These are not all the possible side effects of PRISTIQ. Tell
your healthcare provider about any side effect that bothers you or
does not go away.</p>
<p>Call your doctor for medical advice about side effects. You may
report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store PRISTIQ?</span></p>
<ul>
<li>Store PRISTIQ at 68°F to 77°F (20°C to 25°C).</li>
<li>Do not use PRISTIQ after the expiration date (EXP), which is on
the container. The expiration date refers to the last day of that
month.</li>
<li>Keep PRISTIQ and all medicines out of the reach of
children.</li>
</ul>
<p><span class="Bold">General Information about the safe and
effective use of PRISTIQ</span></p>
<p>Medicines are sometimes used for conditions that are not
mentioned in Medication Guides. Do not use PRISTIQ for a condition
for which it was not prescribed. Do not give PRISTIQ to other
people, even if they have the same symptoms that you have. It may
harm them.</p>
<p>This Medication Guide summarizes the most important information
about PRISTIQ. If you would like more information, talk with your
healthcare provider. You can ask your pharmacist or healthcare
provider for information about PRISTIQ that is written for
healthcare professionals.</p>
<p>For more information, go to www.pristiq.com or call
1-888-PRISTIQ (774-7847).</p>
<p><span class="Bold">What are the ingredients in
PRISTIQ?</span></p>
<p><span class="Bold">Active ingredient:</span> desvenlafaxine</p>
<p><span class="Bold">Inactive ingredients:</span> For the 25 mg
tablet, hypromellose, microcrystalline cellulose, talc, magnesium
stearate, a film coating which consists of polyvinyl alcohol,
polyethylene glycol, talc, titanium dioxide, and iron oxides.</p>
<p>For the 50 mg tablet, hypromellose, microcrystalline cellulose,
talc, magnesium stearate and film coating, which consists of
polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and
iron oxides.</p>
<p>For the 100 mg tablet, hypromellose, microcrystalline cellulose,
talc, magnesium stearate, a film coating which consists of
polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide,
iron oxide and FD&amp;C yellow #6.</p>
<p>This Medication Guide has been approved by the U.S. Food and
Drug Administration.</p>
<p><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-07.jpg"
alt="Logo"></p>
<p>LAB-0539-7</p>
<p>August 2014</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 50 mg Tablet Blister Pack
Carton</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="section-19" id="section-19"></a>
<p class="First"><span class="Bold Italics">ALWAYS DISPENSE WITH
MEDICATION GUIDE</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 0008-1211-50</p>
<p>10 Redipak<span class="Sup">®</span> Blister<br>
Strips of 10 Tablets</p>
<p><span class="Bold">Pristiq</span><span class="Sup">®</span><br>
(desvenlafaxine)<br>
<span class="Bold">Extended-Release Tablets</span></p>
<p><span class="Bold">50 mg*</span></p>
<p>100 Tablets<br>
<span class="Bold">Rx only</span></p>
<div class="Figure"><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-08.jpg"
alt=
"Principal Display Panel - 50 mg Tablet Blister Pack Carton"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 50 mg Tablet Blister
Pack</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="section-20" id="section-20"></a>
<p class="First"><span class="Bold">NDC</span> 0008-1211-50<br>
<span class="Bold">Pristiq</span><span class="Sup">®</span><br>
(desvenlafaxine)</p>
<p><span class="Bold">Extended-Release<br>
Tablets<br>
50 mg*</span></p>
<p>*Equivalent to 76 mg<br>
desvenlafaxine succinate<br>
MADE IN SINGAPORE</p>
<p>PAA041479</p>
<p>Wyeth<span class="Sup">®</span> Phila., PA 19101</p>
<div class="Figure"><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-09.jpg"
alt="Principal Display Panel - 50 mg Tablet Blister Pack"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle
Label</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="section-21" id="section-21"></a>
<p class="First"><span class="Bold Italics">ALWAYS DISPENSE WITH
MEDICATION GUIDE</span></p>
<p><span class="Bold Italics">Pfizer</span><br>
NDC 0008-1211-30</p>
<p><span class="Bold">Pristiq</span><span class="Sup">®</span><br>
(desvenlafaxine)<br>
<span class="Bold">Extended-Release Tablets</span></p>
<p><span class="Bold">50 mg*</span></p>
<p>Unit of Use<br>
30 Tablets</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-10.jpg"
alt="Principal Display Panel - 50 mg Tablet Bottle Label"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 50 mg Tablet Sample
Wallet</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="section-22" id="section-22"></a>
<p class="First"><span class="Bold Italics">ALWAYS DISPENSE WITH
MEDICATION GUIDE</span></p>
<p><span class="Bold">PROFESSIONAL SAMPLE–NOT FOR SALE<br>
NDC 0008-1211-70</span></p>
<p><span class="Bold">Patient Sample Pack</span></p>
<p><span class="Bold">Pristiq<span class="Sup">®</span></span><br>
<span class="Italics">desvenlafazine<br>
<span class="Bold">EXTENDED-RELEASE TABLETS</span></span></p>
<p><span class="Bold">50 mg*</span></p>
<p><span class="Bold">One Card Containing 7 Tablets</span></p>
<p>*Each tablet contains 76 mg desvenlafaxine succinate<br>
equivalent to 50 mg desvenlafaxine</p>
<p><span class="Italics">Please see Full Prescribing Information,
including<br>
boxed warning, and Medication Guide enclosed.</span></p>
<div class="Figure"><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-11.jpg"
alt="Principal Display Panel - 50 mg Tablet Sample Wallet"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 50 mg Tablet Sample
Wallet Carton</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="section-23" id="section-23"></a>
<p class="First"><span class="Bold">PROFESSIONAL SAMPLE–NOT FOR
SALE<br>
NDC 0008-1211-70</span></p>
<p><span class="Bold">5 PATIENT SAMPLE PACKS</span></p>
<p><span class="Bold Italics">ALWAYS DISPENSE WITH MEDICATION
GUIDE</span></p>
<p><span class="Bold">Pristiq<span class="Sup">®</span></span><br>
<span class="Italics">desvenlafazine<br>
<span class="Bold">EXTENDED-RELEASE TABLETS</span></span></p>
<p><span class="Bold">50 mg*<br>
Rx only</span></p>
<p><span class="Italics">Please see Full Prescribing Information,
including boxed warning, and Medication<br>
Guide inside display carton.</span></p>
<div class="Figure"><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-12.jpg"
alt=
"Principal Display Panel - 50 mg Tablet Sample Wallet Carton"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 100 mg Tablet Blister
Pack Carton</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="section-24" id="section-24"></a>
<p class="First"><span class="Bold Italics">ALWAYS DISPENSE WITH
MEDICATION GUIDE</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 0008-1222-50</p>
<p>10 Redipak<span class="Sup">®</span> Blister<br>
Strips of 10 Tablets</p>
<p><span class="Bold">Pristiq</span><span class="Sup">®</span><br>
(desvenlafaxine)<br>
<span class="Bold">Extended-Release Tablets</span></p>
<p><span class="Bold">100 mg*</span></p>
<p>100 Tablets<br>
<span class="Bold">Rx only</span></p>
<div class="Figure"><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-13.jpg"
alt=
"Principal Display Panel - 100 mg Tablet Blister Pack Carton"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 100 mg Tablet Blister
Pack</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="section-25" id="section-25"></a>
<p class="First"><span class="Bold">NDC</span> 0008-1222-50<br>
<span class="Bold">Pristiq</span><span class="Sup">®</span><br>
(desvenlafaxine)</p>
<p><span class="Bold">Extended-Release<br>
Tablets<br>
100 mg*</span></p>
<p>*Equivalent to 152 mg<br>
desvenlafaxine succinate<br>
MADE IN SINGAPORE</p>
<p>PAA041470</p>
<p>Wyeth<span class="Sup">®</span> Phila., PA 19101</p>
<div class="Figure"><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-14.jpg"
alt="Principal Display Panel - 100 mg Tablet Blister Pack"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 100 mg Tablet Bottle
Label</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="section-26" id="section-26"></a>
<p class="First"><span class="Bold Italics">ALWAYS DISPENSE WITH
MEDICATION GUIDE</span></p>
<p><span class="Bold Italics">Pfizer</span><br>
NDC 0008-1222-30</p>
<p><span class="Bold">Pristiq</span><span class="Sup">®</span><br>
(desvenlafaxine)<br>
<span class="Bold">Extended-Release Tablets</span></p>
<p><span class="Bold">100 mg*</span></p>
<p>Unit of Use<br>
30 Tablets</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-15.jpg"
alt="Principal Display Panel - 100 mg Tablet Bottle Label"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL - 25 mg Tablet Bottle
Label</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="section-27" id="section-27"></a>
<p class="First"><span class="Bold Italics">ALWAYS DISPENSE WITH
MEDICATION GUIDE</span></p>
<p><span class="Bold Italics">Pfizer</span><br>
NDC 0008-1210-30</p>
<p><span class="Bold">Pristiq</span><span class="Sup">®</span><br>
(desvenlafaxine)<br>
<span class="Bold">Extended-Release Tablets</span></p>
<p><span class="Bold">25 mg*</span></p>
<p>Unit of Use<br>
30 Tablets</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img src=
"image.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&amp;name=pristiq-16.jpg"
alt="Principal Display Panel - 25 mg Tablet Bottle Label"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INGREDIENTS AND APPEARANCE</a>
<div class="DataElementsTables toggle-content">
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>PRISTIQ
EXTENDED-RELEASE</strong><br>
<span class="contentTableReg">desvenlafaxine succinate tablet,
extended release</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0008-1211</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DESVENLAFAXINE SUCCINATE</strong>
(UNII: ZB22ENF0XR) (DESVENLAFAXINE - UNII:NG99554ANW)</td>
<td class="formItem">DESVENLAFAXINE</td>
<td class="formItem">50 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong> (UNII: 7SEV7J4R1U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong> (UNII:
3WJQ0SDW1A)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong> (UNII:
1K09F3G675)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong> (UNII:
532B59J990)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII:
EX438O2MRT)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2208 (15000
MPA.S)</strong> (UNII: Z78RG6M2N2)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (LIGHT PINK)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">SQUARE (SQUARE PYRAMID)</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">W;50</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0008-1211-50</td>
<td class="formItem">100 in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem"></td>
<td class="formItem">1 in 1 BLISTER PACK; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:0008-1211-01</td>
<td class="formItem">90 in 1 BOTTLE, PLASTIC; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">3</th>
<td class="formItem">NDC:0008-1211-14</td>
<td class="formItem">14 in 1 BOTTLE, PLASTIC; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">4</th>
<td class="formItem">NDC:0008-1211-70</td>
<td class="formItem">7 in 1 BLISTER PACK; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">5</th>
<td class="formItem">NDC:0008-1211-30</td>
<td class="formItem">30 in 1 BOTTLE, PLASTIC; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021992</td>
<td class="formItem">05/01/2008</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>PRISTIQ
EXTENDED-RELEASE</strong><br>
<span class="contentTableReg">desvenlafaxine succinate tablet,
extended release</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0008-1222</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DESVENLAFAXINE SUCCINATE</strong>
(UNII: ZB22ENF0XR) (DESVENLAFAXINE - UNII:NG99554ANW)</td>
<td class="formItem">DESVENLAFAXINE</td>
<td class="formItem">100 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong> (UNII: 7SEV7J4R1U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong> (UNII:
532B59J990)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong> (UNII:
3WJQ0SDW1A)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII:
EX438O2MRT)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong> (UNII:
H77VEI93A8)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2208 (15000
MPA.S)</strong> (UNII: Z78RG6M2N2)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (REDDISH-ORANGE)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">SQUARE (SQUARE PYRAMID)</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">W;100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0008-1222-01</td>
<td class="formItem">90 in 1 BOTTLE, PLASTIC; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:0008-1222-14</td>
<td class="formItem">14 in 1 BOTTLE, PLASTIC; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">3</th>
<td class="formItem">NDC:0008-1222-30</td>
<td class="formItem">30 in 1 BOTTLE, PLASTIC; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">4</th>
<td class="formItem">NDC:0008-1222-50</td>
<td class="formItem">100 in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">4</th>
<td class="formItem"></td>
<td class="formItem">1 in 1 BLISTER PACK; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021992</td>
<td class="formItem">05/01/2008</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>PRISTIQ
EXTENDED-RELEASE</strong><br>
<span class="contentTableReg">desvenlafaxine succinate tablet,
extended release</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0008-1210</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DESVENLAFAXINE SUCCINATE</strong>
(UNII: ZB22ENF0XR) (DESVENLAFAXINE - UNII:NG99554ANW)</td>
<td class="formItem">DESVENLAFAXINE</td>
<td class="formItem">25 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong> (UNII: 7SEV7J4R1U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong> (UNII:
3WJQ0SDW1A)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong> (UNII:
1K09F3G675)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong> (UNII:
532B59J990)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII:
EX438O2MRT)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2208 (15000
MPA.S)</strong> (UNII: Z78RG6M2N2)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (tan)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">SQUARE (SQUARE PYRAMID)</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">W;25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0008-1210-30</td>
<td class="formItem">30 in 1 BOTTLE, PLASTIC; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021992</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Labeler -</span> Wyeth Pharmaceuticals Inc., a
subsidiary of Pfizer Inc. (828831441)</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Establishment</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Name</th>
<th class="formTitle" scope="col">Address</th>
<th class="formTitle" scope="col">ID/FEI</th>
<th class="formTitle" scope="col">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Ireland Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">985098505</td>
<td class="formItem">ANALYSIS(0008-1210, 0008-1222, 0008-1211) ,
MANUFACTURE(0008-1210, 0008-1222, 0008-1211)</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Establishment</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Name</th>
<th class="formTitle" scope="col">Address</th>
<th class="formTitle" scope="col">ID/FEI</th>
<th class="formTitle" scope="col">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Asia Pacific PTE LTD</td>
<td class="formItem"></td>
<td class="formItem">894677996</td>
<td class="formItem">ANALYSIS(0008-1222, 0008-1211, 0008-1210) ,
API MANUFACTURE(0008-1222, 0008-1211, 0008-1210)</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Establishment</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Name</th>
<th class="formTitle" scope="col">Address</th>
<th class="formTitle" scope="col">ID/FEI</th>
<th class="formTitle" scope="col">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Pharmaceuticals LLC</td>
<td class="formItem"></td>
<td class="formItem">829084552</td>
<td class="formItem">ANALYSIS(0008-1222, 0008-1211) ,
LABEL(0008-1210, 0008-1222, 0008-1211) , PACK(0008-1210, 0008-1222,
0008-1211)</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
</ul>
<div class="control-nav"><a class="open-all" href="#">View All
Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
</div>
</div>
</article>
<div class="articlefooternav">
<h2>Find additional resources</h2>
<strong>(also available in the <a href="#leftmenu">left
menu</a>)</strong>
<h3>Safety</h3>
<p><a href="#boxedwarning" target="_blank">Boxed Warnings</a>,
<a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a>, <a href=
"http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety
Recalls</a>, <a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22DESVENLAFAXINE%22+%29"
target="_blank">Presence in Breast Milk</a></p>
<h3>Related Resources</h3>
<p><a href=
"http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=DESVENLAFAXINE"
target="_blank">Medline Plus</a>, <a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=DESVENLAFAXINE"
target="_blank">Clinical Trials</a>, <a href="#pubmed-menu" id=
"pubmed-bottom">PubMed</a>, <a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=DESVENLAFAXINE+SUCCINATE&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></p>
<h3>More Info on this Drug</h3>
<p><a href="#modal-label-archives" class="modal-open">View Label
Archives</a>, <a href="#modal-rx-norm" class=
"modal-open">RxNorm</a>, <a href="#modal-label-rss" class=
"modal-open">Get Label RSS Feed</a></p>
</div>
</div>
<div class="divider"></div>
</div>
</div>
<!-- Label Archives Modal -->
<div class="mfp-hide modal" id="modal-label-archives">
<div class="modal-wrapper">
<header>
<h2>View Label Archives for this drug</h2>
</header>
<div class="top">
<h3 class="long-title">PRISTIQ EXTENDED-RELEASE- desvenlafaxine
succinate tablet, extended release<br></h3>
<h4>Number of versions: 31</h4>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th>Published Date <a class="tip" rel="tooltip" href="#" title=
"&lt;b&gt;Published Date&lt;/b&gt; - The date that a drug label is published on DailyMed for public view. This is distinct from &lt;b&gt;Updated Date&lt;/b&gt;*. &lt;br&gt;&lt;br&gt; *&lt;b&gt;Updated Date&lt;/b&gt; (also known as &lt;b&gt;Effective Time&lt;/b&gt;) - The label revision date included in the SPL.">
(What is this?)</a></th>
<th>Version</th>
<th>Files</th>
</tr>
<tr>
<td>Apr 13, 2015</td>
<td>47 (current)</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=171889">download</a></td>
</tr>
<tr>
<td>Apr 1, 2015</td>
<td>46</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=170810">download</a></td>
</tr>
<tr>
<td>Sep 26, 2014</td>
<td>45</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=152082">download</a></td>
</tr>
<tr>
<td>Sep 18, 2014</td>
<td>44</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=151312">download</a></td>
</tr>
<tr>
<td>Jun 16, 2014</td>
<td>43</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=142525">download</a></td>
</tr>
<tr>
<td>Mar 18, 2014</td>
<td>42</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=133894">download</a></td>
</tr>
<tr>
<td>Jan 7, 2014</td>
<td>41</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=128562">download</a></td>
</tr>
<tr>
<td>Jan 2, 2014</td>
<td>40</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=128211">download</a></td>
</tr>
<tr>
<td>Feb 25, 2013</td>
<td>39</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=101013">download</a></td>
</tr>
<tr>
<td>Dec 20, 2012</td>
<td>38</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=96067">download</a></td>
</tr>
<tr>
<td>Feb 27, 2012</td>
<td>37</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=73999">download</a></td>
</tr>
<tr>
<td>Dec 21, 2011</td>
<td>35</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=69794">download</a></td>
</tr>
<tr>
<td>Dec 6, 2011</td>
<td>32</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=68649">download</a></td>
</tr>
<tr>
<td>Nov 4, 2011</td>
<td>31</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=66517">download</a></td>
</tr>
<tr>
<td>Oct 21, 2011</td>
<td>30</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=65580">download</a></td>
</tr>
<tr>
<td>Aug 8, 2011</td>
<td>29</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=60727">download</a></td>
</tr>
<tr>
<td>Apr 28, 2011</td>
<td>27</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=53000">download</a></td>
</tr>
<tr>
<td>Mar 23, 2011</td>
<td>26</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=50871">download</a></td>
</tr>
<tr>
<td>Jan 26, 2011</td>
<td>22</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=48059">download</a></td>
</tr>
<tr>
<td>Nov 9, 2010</td>
<td>18</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=42461">download</a></td>
</tr>
<tr>
<td>Oct 22, 2010</td>
<td>16</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=41828">download</a></td>
</tr>
<tr>
<td>Jun 4, 2010</td>
<td>12</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=19696">download</a></td>
</tr>
<tr>
<td>Apr 26, 2010</td>
<td>11</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=18736">download</a></td>
</tr>
<tr>
<td>Dec 24, 2009</td>
<td>9</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=14786">download</a></td>
</tr>
<tr>
<td>Dec 8, 2009</td>
<td>8</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=14146">download</a></td>
</tr>
<tr>
<td>Nov 19, 2009</td>
<td>7</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=13619">download</a></td>
</tr>
<tr>
<td>Oct 14, 2009</td>
<td>6</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=12822">download</a></td>
</tr>
<tr>
<td>Sep 15, 2009</td>
<td>5</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=12136">download</a></td>
</tr>
<tr>
<td>Sep 9, 2009</td>
<td>4</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=12038">download</a></td>
</tr>
<tr>
<td>Feb 5, 2009</td>
<td>3</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=9969">download</a></td>
</tr>
<tr>
<td>Mar 27, 2008</td>
<td>1</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=7623">download</a></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- RxNorm Modal -->
<div class="mfp-hide modal" id="modal-rx-norm">
<div class="modal-wrapper">
<header>
<h2>RxNorm</h2>
</header>
<div class="top">
<h3 class="long-title">PRISTIQ EXTENDED-RELEASE- desvenlafaxine
succinate tablet, extended release<br></h3>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th></th>
<th>RxCUI</th>
<th>RxNorm NAME</th>
<th>RxTTY</th>
</tr>
<tr class="psn-rxtty">
<td>1</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790264">790264</a></td>
<td>desvenlafaxine 100 MG 24HR Extended Release Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>2</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790264">790264</a></td>
<td>24 HR Desvenlafaxine 100 MG Extended Release Oral Tablet</td>
<td>SCD</td>
</tr>
<tr>
<td>3</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790264">790264</a></td>
<td>desvenlafaxine 100 MG (as desvenlafaxine fumarate 150.9 MG) 24
HR Extended Release Oral Tablet</td>
<td>SY</td>
</tr>
<tr>
<td>4</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790264">790264</a></td>
<td>desvenlafaxine 100 MG (as desvenlavaxine succinate 152 MG) 24
HR Extended Release Oral Tablet</td>
<td>SY</td>
</tr>
<tr>
<td>5</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790264">790264</a></td>
<td>desvenlafaxine 100 MG 24 HR Extended Release Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>6</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790267">790267</a></td>
<td>Pristiq 100 MG 24HR Extended Release Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>7</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790267">790267</a></td>
<td>24 HR Desvenlafaxine 100 MG Extended Release Oral Tablet
[Pristiq]</td>
<td>SBD</td>
</tr>
<tr>
<td>8</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790267">790267</a></td>
<td>24 HR Pristiq 100 MG Extended Release Oral Tablet</td>
<td>SY</td>
</tr>
<tr>
<td>9</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790267">790267</a></td>
<td>Pristiq 100 MG (desvenlafaxine succinate 152 MG) 24 HR Extended
Release Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>10</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790288">790288</a></td>
<td>desvenlafaxine 50 MG 24HR Extended Release Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>11</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790288">790288</a></td>
<td>24 HR Desvenlafaxine 50 MG Extended Release Oral Tablet</td>
<td>SCD</td>
</tr>
<tr>
<td>12</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790288">790288</a></td>
<td>desvenlafaxine 50 MG (as desvenlavaxine fumarate 75.45 MG) 24
HR Extended Release Oral Tablet</td>
<td>SY</td>
</tr>
<tr>
<td>13</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790288">790288</a></td>
<td>desvenlafaxine 50 MG (as desvenlavaxine succinate 76 MG) 24 HR
Extended Release Oral Tablet</td>
<td>SY</td>
</tr>
<tr>
<td>14</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790288">790288</a></td>
<td>desvenlafaxine 50 MG 24 HR Extended Release Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>15</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790290">790290</a></td>
<td>Pristiq 50 MG 24HR Extended Release Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>16</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790290">790290</a></td>
<td>24 HR Desvenlafaxine 50 MG Extended Release Oral Tablet
[Pristiq]</td>
<td>SBD</td>
</tr>
<tr>
<td>17</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790290">790290</a></td>
<td>24 HR Pristiq 50 MG Extended Release Oral Tablet</td>
<td>SY</td>
</tr>
<tr>
<td>18</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=790290">790290</a></td>
<td>Pristiq 50 MG (desvenlafaxine succinate 76 MG) 24 HR Extended
Release Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>19</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1607617">1607617</a></td>
<td>desvenlafaxine 25 MG 24HR Extended Release Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>20</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1607617">1607617</a></td>
<td>24 HR Desvenlafaxine 25 MG Extended Release Oral Tablet</td>
<td>SCD</td>
</tr>
<tr>
<td>21</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1607617">1607617</a></td>
<td>desvenlafaxine 25 mg (as desvenlafaxine succinate 38 MG) 24 HR
Extended Release Oral Tablet</td>
<td>SY</td>
</tr>
<tr>
<td>22</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1607617">1607617</a></td>
<td>desvenlafaxine 25 MG 24 HR Extended Release Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>23</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1607619">1607619</a></td>
<td>Pristiq 25 MG 24HR Extended Release Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>24</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1607619">1607619</a></td>
<td>24 HR Desvenlafaxine 25 MG Extended Release Oral Tablet
[Pristiq]</td>
<td>SBD</td>
</tr>
<tr>
<td>25</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1607619">1607619</a></td>
<td>Pristiq 25 mg (as desvenlafaxine succinate 38 MG) 24 HR
Extended Release Oral Tablet</td>
<td>SY</td>
</tr>
<tr>
<td>26</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1607619">1607619</a></td>
<td>Pristiq 25 MG 24 HR Extended Release Oral Tablet</td>
<td>SY</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- Label RSS Modal -->
<div class="mfp-hide modal" id="modal-label-rss">
<header>
<h2>Get Label RSS Feed for this Drug</h2>
</header>
<div class="top">
<h3 class="long-title">PRISTIQ EXTENDED-RELEASE- desvenlafaxine
succinate tablet, extended release<br></h3>
</div>
<div class="modal-content">
<h4>To receive this label RSS feed</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href=
"https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce"
target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce</a></p>
<h4>To receive all DailyMed Updates for the last seven days</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>
<h4>What will I get with the DailyMed RSS feed?</h4>
<p>DailyMed will deliver notification of updates and additions to
Drug Label information currently shown on this site through its RSS
feed.</p>
<p>DailyMed will deliver this notification to your desktop, Web
browser, or e-mail depending on the RSS Reader you select to use.
To view updated drug label links, paste the RSS feed address (URL)
shown below into a RSS reader, or use a browser which supports RSS
feeds, such as Safari for Mac OS X.</p>
<h4>How to discontinue the RSS feed</h4>
<p>If you no longer wish to have this DailyMed RSS service, simply
delete the copied URL from your RSS Reader.</p>
<a href="/dailymed/rss-updates.cfm" class="rss-icon"></a> <a href=
"/dailymed/rss-updates.cfm">More about getting RSS News &amp;
Updates from DailyMed</a></div>
</div>
<!-- RxImage no more notification modal -->
<div class="mfp-hide modal" id="no-pill-photo-warning-modal">
<div class="modal-content">
<h4>Why is DailyMed no longer displaying pill images on the Search
Results and Drug Info pages?</h4>
<br>
<p>Due to inconsistencies between the drug labels on DailyMed and
the pill images provided by <a href=
"https://rximage.nlm.nih.gov/docs/doku.php?id=rximageapi_support"
target="_blank">RxImage</a>, we no longer display the RxImage pill
images associated with drug labels.</p>
<p>We anticipate reposting the images once we are able identify and
filter out images that do not match the information provided in the
drug labels.</p>
</div>
</div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<div class="mobilenav no-js">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
<footer class="mainFooter">
<div class="container">
<div class="three columns">
<div class="nihnlmlogoprint"><img src=
"/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>
<a href="//www.nlm.nih.gov/" class="logo" title=
"National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png"
width="109" height="37" alt=
"National Library of Medicine | National Institutes of Health"
title=
"National Library of Medicine | National Institutes of Health"></a></div>
<div id="share" class="thirteen columns">
<div class="footer-links">
<ul class="primary">
<li><a href="/dailymed/about-dailymed.cfm" title=
"About DailyMed">About DailyMed</a><span>|</span></li>
<li><a href="/dailymed/contact-us.cfm" title="Contact Us">Contact
Us</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/copyright.html" title="Copyright"
target="_blank" rel="bookmark">Copyright</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/privacy.html" title="Privacy"
target="_blank" rel="bookmark">Privacy</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/accessibility.html" title=
"Web Accessibility" target="_blank" rel="bookmark">Web
Accessibility</a></li>
</ul>
<ul class="secondary">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">National Institutes of Health</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">U.S. National Library of Medicine</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<ul class="secondary mobile">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">NIH</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">NLM</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<div class="social">Share <!-- AddThis Button BEGIN -->
 <noscript>: JavaScript needed for Sharing tools</noscript>
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0APRISTIQ%20EXTENDED%2DRELEASE%2D%20Desvenlafaxine%20Succinate%20Tablet%2C%20Extended%20Release%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D0f43610c%2Df290%2D46ea%2Dd186%2D4f998ed99fce%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="width: 16px; height: 16px"><span style=
"left: -9999px; position: absolute;">Bookmark &amp; Share</span>
<img style="width:17px; margin-top: -2px;" src=
"/dailymed/images/addthis-image.jpg" alt=
"Bookmark &amp; Share"></a></div>
<!-- AddThis Button END --></div>
</div>
</div>
</div>
<div class="divider"></div>
</footer>
<div class="divider"></div>
</div>
<div class="to-top"></div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<script type="text/javascript" src=
"//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery == 'undefined')
        {  
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');
        }
</script> <script type="text/javascript">
        var basepath = "/dailymed";
;
        var availableClasses =  new Array();
;
        for(var i = 0; i < availableClasses.length; i++){
                availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();
        }
        var labeltitle = "PRISTIQ  EXTENDED-RELEASE- desvenlafaxine succinate tablet, extended release <br>";
;
        var emailLink = "";
;
        var emailrequest = "0";
;
</script> <script src=
"/dailymed/scripts/javascript-html-attribute-encoding.min.js">
</script> <script src="/dailymed/scripts/spin.min.js">
</script> <script src="/dailymed/scripts/scripts.min.js?v=2">
</script> <script type='text/javascript' src=
"//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery.ui == 'undefined')
        {
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');
            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="/dailymed/css/jquery-ui-1.10.4.custom.min.css">');
        }
        else{
            document.write('<link rel="stylesheet" href="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');
        }
</script> <script type='text/javascript' src=
'/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'>
</script> <script type="text/javascript" src=
"/dailymed/scripts/jquery.placeholder.min.js">
</script> <script src=
"//www.accessdata.fda.gov/spl/stylesheet/spl.js" type=
"text/javascript" charset="utf-8">
/* */
</script> <!-- Magnific Popup core JS file -->
 <script src="/dailymed/scripts/jquery.magnific-popup.min.js">
</script> <script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <script>
 var ignore_onbeforeunload = false;

 $("a").on('click',function(){
    if(ignore_onbeforeunload){
        ignore_onbeforeunload = false;
    }
})

$("a[href^='mailto'], a[href$='zip']").on('click',function(){
    ignore_onbeforeunload = true;
});


$(window).on('beforeunload', function(){
    if (!ignore_onbeforeunload){
        // Only run the loading icon if changing the page takes longer than 200ms
        setTimeout(function(){
            // Fade in the grey screen
            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"><\/div>').fadeIn('fast'));
            var opts = {
                  lines: 12 // The number of lines to draw
                , length: 14 // The length of each line
                , width: 5 // The line thickness
                , radius: 14 // The radius of the inner circle
                , scale: 1 // Scales overall size of the spinner
                , corners: 1 // Corner roundness (0..1)
                , color: '#fff' 
                , opacity: 0.25 // Opacity of the lines
                , rotate: 0 // The rotation offset
                , direction: 1 // 1: clockwise, -1: counterclockwise
                , speed: 1 // Rounds per second
                , trail: 60 // Afterglow percentage
                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS
                , zIndex: 2e9 // The z-index (defaults to 2000000000)
                , className: 'spinner' // The CSS class to assign to the spinner
                , top: '50%' // Top position relative to parent
                , left: '50%' // Left position relative to parent
                , shadow: false // Whether to render a shadow
                , hwaccel: false // Whether to use hardware acceleration
                , position: 'absolute' // Element positioning
                }
            var spinner = new Spinner(opts).spin();
            $('.loading-wrapper').append(spinner.el);
        }, 200);
    }

    //ignore_onbeforeunload = false;
});
</script> <!-- START OF SmartSource Data Collector TAG -->
<!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. -->
<!-- Version: 9.4.0 -->
<!-- Tag Builder Version: 3.3  -->
<!-- Created: 1/25/2012 11:57:33 PM -->
<script type="text/javascript" src=
"/dailymed/scripts/webtrends.min.js">
</script> 
<!-- =================================================================================== -->
<!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
<!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
<!-- =================================================================================== -->
<script type="text/javascript">
//<![CDATA[
var _tag=new WebTrends();
_tag.dcsGetId();
//]]>
</script> <script type="text/javascript">
//<![CDATA[
_tag.dcsCustom=function(){
// Add custom parameters here.
//_tag.DCSext.param_name=param_value;
_tag.DCSext.dcsid=_tag.dcsid
}
_tag.trackAllEvents=true;
_tag.dcsCollect();
//]]>
</script> <noscript>
<div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src=
"//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"></div>
</noscript> <!-- END OF SmartSource Data Collector TAG -->
 <script type="text/javascript">
    setTimeout(function(){var a=document.createElement("script");
    var b=document.getElementsByTagName("script")[0];
    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);
    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);
</script> <script type="text/javascript">
    function getParameterByName(name) {
        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");
        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),
            results = regex.exec(location.search);
        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));
    }
    /* Tracking label type on search pages */
    function CE_READY() {
        if(!getParameterByName('labeltype')){
           CE2.set(1, "No Label Type");
        }
        else{
            var labeltype = getParameterByName('labeltype');
            if(labeltype == 'all'){
                CE2.set(1, "All");
            }
            else if(labeltype == 'human'){
                CE2.set(1, "Human");
            }
            else if(labeltype == 'animal'){
                CE2.set(1, "Animal");
            }
            else{
                CE2.set(1, "Unknown");
            }
        }
    }
</script> <!-- DAP Universal Analytics -->
 <script language="javascript" id="_fed_an_ua_tag" src=
"/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&amp;subagency=NIH&amp;enhlink=true&amp;dclink=true">
</script> <script src="/dailymed/scripts/preview-text.min.js">
</script>
</body>
</html>
